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Kisspeptins signal via the G-protein coupled receptor, KISS1R, and act as 
metastasis suppressors in numerous cancers.  In estrogen receptor (ERα)-negative breast 
cancer cells, however, KISS1R signaling promotes cell invasion by activating the 
epidermal growth factor receptor (EGFR).  Unfortunately, clinical success of anti-EGFR 
therapeutics has been limited, as patients often develop drug resistance.  Recently, 
another receptor tyrosine kinase, AXL, has been shown to promote breast cancer drug 
resistance.  We hypothesize that KISS1R promotes EGFR expression and induces breast 
cancer drug resistance.  We demonstrated that KISS1R increases EGFR transcription, by 
increasing SP-1 binding to the EGFR promoter, as demonstrated by chromatin 
immunoprecipitation experiments.  Additionally, we discovered that KISS1R signaling 
promotes drug resistance of ERα-negative breast cancer cells, since KISS1R 
overexpression decreased intracellular doxorubicin accumulation and decreased 
sensitivity.  KISS1R also promotes AXL expression and AXL depletion restored 
doxorubicin sensitivity.  Overall, our results suggest that KISS1R signaling promotes 
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1.1 Breast Cancer 
According to the Canadian Cancer Society, breast cancer is the most commonly 
diagnosed cancer among Canadian women and is the second leading cause of cancer-
related deaths in the country.  Breast cancer affects 1 in 9 Canadian women and accounts 
for 26% of all new diagnosed cancers in 2014.  It is estimated that this year in Canada, 
24,400 women and 210 men will be diagnosed with breast cancer, and 5,000 women are 
expected to die from the disease†.   
1.1.1 Breast Cancer Staging and Classification 
Normal breast epithelium forms a well-defined uniform layer, forming milk ducts 
or glands of the breast.  In contrast to healthy cells, breast cancer cells have undergone 
genetic changes, enabling them to develop a malignant phenotype.  These cancer cells 
exhibit specific alterations in cellular processes, including: decreased apoptosis and 
immune destruction, as well as increased proliferation rate, invasion, and genomic 
instability, resulting in tumourigenesis (1).  The genetic changes that drive 
tumourigenesis are often acquired through spontaneous mutations, however they can also 
be inherited.  Approximately 5-10% of all breast cancers have a hereditary background 
(2).  Germline mutations in BRCA 1/2, tumour suppressor genes implicated in 
maintaining genomic stability through their role in DNA repair, increase the risk of 
developing breast cancer by the age of 70 to 45-87% (3).       
 Breast cancer staging describes the extent or spreading of cancer in the body.  The 
American Joint Committee on Cancer (AJCC) has developed a classification system, 
which describes the severity of a patient’s cancer based on the location and size of the 
primary tumour and the metastatic extent.  The initial stage, stage 0, is when abnormal 
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breast cells are present, appearing as pinpoint lesions, yet a primary tumour cannot be 
detected (4).  Most often, breast cancers arise from abnormally proliferating cells in either 
the duct lining or lobular tissue of the mammary glands and are referred to as ductal and 
lobular hyperplasias, respectively.  Once these cells begin to form a small mass, they are 
respectively termed, ductal carcinoma in situ (DCIS) and lobular carcinoma in situ 
(LCIS).  As cancer progresses, cells become more aggressive and begin to invade into 
surrounding tissues, the cancer is referred to as invasive ductal carcinoma (IDC) or 
invasive lobular carcinoma (ILC).  Stages I-III are classified based on the size of the 
primary tumour and the degree that the breast cancer cells have spread to the lymph 
nodes surrounding the breast (5).  In the final stage, stage IV, breast cancer cells have 
spread to distant organs or tissue sites, most often brain, bone, liver and lung, at which 
point the cancer becomes extremely difficult to treat and patient prognosis is very poor 
(4) (Figure 1.1).    
Additionally, breast tumours can be described based on how abnormal the tumour 
cells and tissue look under a microscope, termed tumour grade.  Generally, tumours are 
graded as 1, 2, 3 or 4, depending on the degree of abnormality. Grade 1 tumour cells 
closely resemble normal breast tissue while Grade 4 tumour cells are highly abnormal or 
undifferentiated.  Grade 3 and Grade 4 tumours tend to grow rapidly and spread faster 





Figure 1.1.  Breast cancer progression. Healthy normal epithelium cells undergo 
genetic or epigenetic changes resulting in deregulated cell growth and ductal hyperplasia.  
As cells begin to lose their normal morphology, they progress to an appearance indicative 
of ductal carcinoma in situ.  Continued uncontrolled growth and dedifferentiation results 
in extremely invasive cells capable of metastasizing to distant tissues.  Schematic is from 





1.1.2 Breast Carcinoma Subtypes 
Human breast tumours are very genotypically and phenotypically diverse (7).  
Although breast cancer is a very heterogeneous disease, advances in DNA microarray 
technology has allowed tumours to be classified into subtypes, based on gene expression 
patterns (7). One method of classification, currently used clinically, is based on hormone 
receptor status: estrogen receptor (ER), progesterone receptor (PR) and human epidermal 
growth factor receptor 2 (HER-2) (Table 1.1).  Most breast cancers are luminal tumours, 
accounting for 70% of all breast cancers, where cancer cells arise from the luminal lining 
of the mammary ducts.  These luminal breast cancers typically are positive for ER, PR 
expression and negative for HER-2 overexpression, classifying them as hormone-receptor 
positive cancers.  Hormone-receptor positive tumours respond well to tamoxifen, a 
competitive antagonist of ER, which decreases the proliferative effects of estrogen 
signaling (8).  Another subtype, classified as HER-2 positive, accounts for 10-15% of all 
breast tumours.  HER-2 is a biomarker for breast cancer due to its ability to promote cell 
proliferation in a ligand independent manner (9).  HER-2 positive tumours are negative 
for ER and PR expression, however, do overexpress HER-2, typically due to 
amplification of its encoding gene ERBB2 (10).  Monoclonal antibody treatments against 
HER-2 have been developed, including Trastuzumab (Herceptin), and are used clinically 
to treat and selectively target HER-2 positive tumours (11).  Patients treated with these 
targeted hormonal therapies such as Trastuzumab have decreased side effects and better 




Table 1.1 Breast cancer subtypes.   
 




Estrogen Receptor (ER) 






Triple Negative (15-20%) No ER, PR or HER-2 None 
 
1.1.3 Triple Negative Breast Cancer 
Some tumours, however, do not express ER, PR nor overexpress HER-2 and are 
thus defined as triple-negative breast cancers (TNBC) (Table 1.1).  TNBCs account for 
15-20% of all breast carcinomas.  TNBC patients have a very poor prognosis, because 
their tumours tend to be very aggressive, be highly metastatic, and patients display high 
recurrence rates after adjuvant therapy (13).  These patients, typically women under 50 
years of age, lack targeted therapies and have a low 5-year survival rate (14).  Studies 
have shown TNBC tumours express high levels of epithelial-to-mesenchymal transition 
(EMT) marker vimentin and proliferative promoting protein Ki-67 (10, 15).  
Additionally, mutations in the tumour suppressor genes phosphatase and tensin homolog 
(PTEN) and retinoblastoma (RB1) as well as the oncogene KRAS have been associated 
with the TNBC subtype (16-18).  Interestingly, TNBC expression profiles also share 
similarities with breast cancers that have mutations in the DNA repair protein BRCA1, 
and emerging data suggests that TNBC patients are more likely to have BRCA1 mutations 
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than patients with non-TNBC (13, 19).  This suggests that the loss of BRCA1 function 
may play a critical role in the development of TNBC (10).    
A number of studies have also associated TNBC with increased expression of the 
epidermal growth factor receptor (EGFR), ranging from 41-71% (10, 20-22).  EGFR, 
similar to HER-2, signals via PI3K/Akt pathways in order to increase cell proliferation 
and migration.  A significant correlation between EGFR expression and increased tumour 
grade along with distant metastasis has been shown in TNBC tumours (21).  EGFR has 
also been implicated as being a marker for chemotherapy response rates for TNBC 
patients.  Through retrospective analysis of the relationship between EGFR expression, 
chemotherapy response and overall survival, for each breast cancer subtype, TNBC 
patients with EGFR overexpression demonstrated the poorest chemotherapeutic response 
and decreased overall survival (22).  Therefore, EGFR may be a potential biomarker for 
poor prognosis in TNBC patients, due to increased metastasis and lower response rates to 
chemotherapies seen in patients with EGFR overexpression.  
The current standard of care to treat TNBC is conventional chemotherapies 
including anthracyclines, taxanes and platinum based drugs, all of which are cytotoxic 
agents (23).   Although TNBC initially has a better response rate to these therapies 
compared to endocrine-responsive or HER-2 positive breast carcinomas, patients have 
poorer overall survival due to high recurrence rates and increased metastasis (22).  Due to 
the identification of upregulated molecular pathways or receptors in TNBC, including 
EGFR, targeted therapies have been developed.  Many of these EGFR-targeted therapies 
have reached phase II clinical trials; however the results have been disappointing and 
none of these therapies have been proven effective monotherapies in treating TNBC (10, 
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23).  Due to the current lack of targeted therapies available to patients with TNBC, 
finding molecular targets that can not only be inhibited to improve patients prognosis, but 
that also regulate previously characterized TNBC biomarkers would be a critical 
discovery in order to improve TNBC patient care.  
1.1.4 Metastatic Cascade 
Metastasis is a complex process by which cancer cells break away from their 
primary tumor and travel to secondary sites within the body either through the circulatory 
or lymphatic system. Prognosis is extremely promising when breast carcinomas are 
confined to breast tissue, as cure rates exceed 90%. However, long-term survival is 
significantly decreased after metastasis occurs (24).  There are currently no therapies 
clinically available that specifically target metastasis (25). 
In order for metastasis to occur, the tumor must undergo a number of sequential 
steps, including angiogenesis, invasion of cells into surrounding tissue, intravasation, 
dissemination throughout the circulatory and lymphatic systems, extravasation at distant 
tissue sites and an establishment of a new tumour (26) (Figure 1.2).  The initial step of 
the cascade involves a subpopulation of the primary tumor acquiring a mutation to cause 
a malignant phenotype.  The growth and survival of these primary tumour cells depends 
on the process of angiogenesis, where new blood vessels form from previous vasculature.  
Once these cancer cells have acquired their own blood supply, increased genomic 
instability can cause cells to lose polarity and cell-cell adhesive properties in order to gain 
the ability to migrate and invade by a process called EMT.  Epithelial cells that have 
undergone EMT display decreased expression of adhesion molecules such as E-cadherin, 
and increased expression of matrix metalloproteinases (such as MMP-2, -9, -13 and -14), 
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N-cadherin, vimentin and transcription factors including Snail-Slug to acquire a 
mesenchymal phenotype (26).  Under normal physiological conditions, epithelial cells are 
organized and polarized, and signals are conveyed by cell-cell connections accomplished 
by gap and tight junctions (27). Once cells have undergone EMT, they can then invade 
the underlying basement membrane, local extracellular matrix and stroma.  This is 
primarily due to expression of MMPs.  Next, tumor cells intravasate into blood vessels or 
enter circulation through the lymphatic system. There are fewer tight junctions between 
endothelial cells of the lymphatic system, compared to the cardiovascular system, 
potentially making it easier for tumor cells to enter the lymphatic system (28).  Once in 
cardiovascular or lymphatic circulation, tumor cells must survive by evading immune 
system destruction.  At distant sites within the body, the cancer cells arrest in capillary 
beds, bind to endothelial cells and extravasate into the surrounding tissue (29).  Similar to 
primary tumor growth, the secondary tumor requires angiogenesis to supply the growing 
tumor.  Once secondary tumors are established successful medical intervention is limited 











Figure 1.2. Schematic representation of the metastatic cascade.  The initial step is the 
formation of the primary tumour through increased cell proliferation (a).  Cells then lose 
their cell-cell adhesive properties and invade the basement membrane (b).  This allows 
cells to enter the circulation either via lymphatic or circulatory system (c).  Some cancer 
cells will survive in circulation and arrest in distant capillary beds (d).  Cells will then 
extravasate to secondary sites (e) and form secondary tumours (f).  Adapted from Steeg et 






1.2 Multidrug Resistance 
Multidrug resistance is a characteristic of malignant cells, which exhibit resistance 
to multiple drug therapies.  The development of resistance to cancer drug therapies 
treatments remains a major challenge in oncology.  This resistance can precede any drug 
exposure (de novo), or can be acquired resistance, due to the adaptation of cells to 
treatment (31).  Drug resistance of cancer cells has been studied since the 1960s (32), 
however, recently increased availability of sequencing technologies, including next 
generation sequencing, has fostered a better understanding of the complexity of cancer 
cell drug resistance.   
1.2.1 Mechanisms of Drug Resistance 
The best studied mechanism by which many types of cancer cells become 
resistant to therapies is through the up-regulation of drug efflux transporters.  These drug 
efflux transporters are members of the ATP-binding cassette (ABC) transporter family, 
and are able to pump out drug molecules, against their concentration gradient, to decrease 
intracellular accumulation and pharmacological effects (33).  There are 7 subfamilies of 
these transporters, many of which are related to drug resistance (34).  Initially, P-
glycoprotein 1 (P-gp) and multidrug resistance protein 1 (MRP1), encoded by the genes 
ABCB1 and ABCC1 respectively, were identified as being drug efflux proteins that 
contributed to the resistance of cancer cells to conventional chemotherapeutic agents.  
However, cancer cell lines devoid of these two proteins were generated that still had a 
drug resistant phenotype, which lead to the further investigation and eventual 
identification of breast cancer resistance protein (BCRP) and other members of the MRP 
family, including multidrug resistant protein 4 (MRP4) (35).  P-gp, MRP1, BCRP and 
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MRP4 are highly expressed in the brain, helping form the blood-brain-barrier, as well as 
in the lungs, testis and placenta.  These transporters function physiologically in normal 
tissues to actively pump out endogenous substances including cGMP, steroids and bile 
acids, as well as function as a defense mechanism against cellular toxins.  Conventional 
chemotherapies, such as the anthracycline antibiotic, doxorubicin, are among the 
substrates for these transporters and a link between drug efflux and drug resistance has 
been established (36).  Other anticancer agents that are substrates of these drug efflux 
transporters include taxanes and receptor tyrosine kinase inhibitors (TKIs) (34).  Many 
inhibitors of these drug efflux transporters have been identified, however, their use 
clinically has not been very successful (37) (Table 1.2).  For example, Fumitremorgin C 
(FTC), a highly specific fungal toxin to BCRP, produced severe neurotoxic effects in 
mice and other mammals, preventing use clinically (38).  Therefore, due to the common 
decrease in chemosensitivity observed in TNBC patients, and the lack of clinical success 
using drug efflux transporter inhibitors, it is critical to determine the underlying 
mechanisms regulating drug resistance in order to increase the quality of patient care. 
Recently, a role of microRNAs (miRNAs) has been established in the regulation 
of drug resistance.  These small, non-coding RNA molecules are able to bind to mRNA in 
order to prevent translation and accelerate degradation (39).  Although over 50 miRNAs 
have been identified as having important roles in drug resistance, a number of them, 
including, miR-19, miR-21, and miR-205, specifically target PTEN, implicating the 
PI3K/Akt pathway as a key signaling mechanism by which drug resistance is required 
(40).  It is unknown whether activation of the PI3K/Akt pathway increases resistance by 
directly affecting drug efflux transporter expression or by an indirect mechanism, by 
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affecting cell survival signaling (40).  In addition to altered miRNA expression, drug-
resistant cancer cells have also been shown to exhibit epigenetic changes.  One of the best 
examples of epigenetic alterations leading to breast cancer drug resistance is the 
repression of drug efflux transport protein P-gp through hypomethylation and histone H3 
lysine 9 acetylation of the P-gp promoter in MCF-7, human breast cancer cells (41).   
Drug resistance can also arise from an alteration in the drug’s target, due to 
mutation.   An example of this occurring in lung cancer is the T790M mutation in EGFR, 
which is present in half of all patients resistant to EGFR inhibitors (42).  Additionally, 
resistance can occur due to the non-linear, highly interconnected nature of all major 
signaling pathways of the cell (43).  Due to the presence of positive and negative 
feedback mechanisms as well as dynamic complex signaling, simply understanding the 
protein components of a pathway is not sufficient to target its effects.  A better 
understanding of the integrated signaling is required to develop cancer therapeutics with a 
decreased potential for drug resistance.   
Additionally, more work is required to better understand the underlying 
mechanisms by which cancer cells acquire resistance in order to better predict patient 













Table 1.2 Clinical outcomes of drug efflux transporter inhibitors. Adapted from 






Clinical Use in 
Cancer 
    P-gp MRP-1 BCRP   
P-gp Verapamil X   None 
 LY335979 X   Phase III in leukemia 
 OC144-093 X  X None 
MRP MK571  X  None 
 Myricetin  X  None 
 Sulindac  X  Phase II in leukemia 
BCRP Fumitremorgin C   X None 
  Ko143     X None 
 
1.2.2 Drug Resistance in TNBC Patients 
Although drug resistance is a major obstacle when treating any subtype of breast 
cancer, highly aggressive cancers, such as TNBC tumours, tend to be even more resistant 
to therapies.  In fact, the major cause of metastatic treatment failure in TNBC patients is 
due to multidrug resistance to standard therapies (14).  Treatment for TNBC patients is 
limited to surgery and conventional chemotherapies, including taxanes and anthracyclines 
(44).  Taxanes, including paclitaxel, inhibit mitosis by stabilizing microtubules in order to 
induce apoptosis (44).  Anthracyclines, an example being doxorubicin, however, work by 
intercalating into DNA and inhibiting topoisomerase II activity.  Predominantly, 
resistance to taxanes and anthracyclines is due to decreased intracellular drug 
accumulation through an increase in drug efflux via up-regulation of drug efflux 
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transporter proteins (45).  Due to the lack of targeted therapies available to treat TNBC, 
these patients have the worst prognosis and outcome of all breast cancer subtypes (46).  
Although initially having a higher response rate to chemotherapy, TNBC patients have 
the lowest overall survival rate after treatment, compared to other breast cancer subtypes.  
Also, these patients have shorter rates of survival after metastasis has occurred (47).  This 
low survival rate can be attributed to the highly adaptive response of TNBC tumours, 
leading to acquired resistance to chemotherapeutics (48).  Due to the current poor 
prognosis of TNBC patients, discovering new targets that can improve treatment and 
reduce resistance to chemotherapy is required, as is the focus of this study. 
 
1.3 G-Protein Coupled Receptors  
 G-protein coupled receptors (GPCRs) are receptors characterized by seven-
transmembrane α-helical domains that are able to facilitate the transduction of 
extracellular signals into intracellular events.  This transduction occurs via activation of 
heterotrimeric G-proteins (consisting of an alpha, beta and gamma subunit) (49).  The 
superfamily of GPCRs is very diverse and regulates a large range of cellular responses, 
specifically to many neurotransmitters and hormones (50).  Due to the pivotal roles 
GPCRs play in regulating healthy cell physiology, their signaling pathways are often 
associated with pathogenesis.  It is estimated that 40-50% of clinically approved 
therapeutics target GPCRs in a variety of diseases, including cancer, as well as metabolic 
and neurodegenerative diseases (51, 52). 
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1.3.1 GPCRs in Cancer 
 GPCRs have been implicated in the pathogenesis of cancer, by regulating cell 
growth, proliferation, apoptosis and differentiation, as well as angiogenesis and 
metastasis (49).  Overexpression of these receptors can increase downstream signaling 
leading to increased tumourigenesis, as demonstrated by endothelin receptors stimulating 
angiogenesis in several cancers (53).  Additionally, some GPCRs, including the 
lysophosphatidic-acid receptors in ovarian cancer, can actually increase the production of 
their own ligands, leading to further activation of downstream events through an 
autocrine loop (54).  However, to date, very little is known about the role GPCRs play in 
TNBC. 
1.3.2 KISS1 and KISS1R Discovery and Expression 
KISS1, originally classified as a metastasis-suppressor gene in melanoma cells, 
was named in reference to its place of discovery- Hershey, Pennsylvania, home of the 
famous Hershey’s Kisses (55).  This original study showed that an unknown sequence, 
now termed the KISS1 gene, was found only in non-metastatic neo6/C8161.1 melanoma 
cells compared to metastatic C8161 cells.  Additionally, when these metastatic C8161 
melanoma cells were transfected with KISS1 and injected into nude immunodeficient 
mice, to perform a spontaneous metastasis assay, cells transfected with KISS1 had no 
effect on primary tumour growth but did significantly reduce lymph node involvement 
and lung metastasis, identifying KISS1 as a potential negative regulator of metastasis 
(56).   
Although originally identified as having high expression in the placenta, 
expression of KISS1 has also been detected in the brain, pancreas, liver, small intestine, 
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heart, skeletal muscle, breast, kidneys, and lungs (57).  It is now known that KISS1 is 
translated into a 145 amino acid peptide, kisspeptin-145, which is subsequently cleaved 
into smaller blood borne, secreted peptides, kisspeptin-54, -14, -13 and -10 (58) (Figure 
1.3). These shorter kisspeptins are cleaved from the C-terminus of kisspeptin-145 by 
furin, MMP-2, -9, and -14 or prohormone convertases (58).  Kisspeptin-10 (KP-10) is the 
shortest biologically active kisspeptin, with a sequence of YNWNSFGLRF-NH2, and this 
sequence is highly conserved among vertebrates, only differing by one amino acid 
substitution between human, mouse, sheep and xenopus (59).   
Five years after the discovery of KISS1, three independent groups identified 
kisspeptins as being ligands for the orphan GPCR, KISS1R, previously termed 
H0T7T175, AXOR12 or GPR54 (60-62).  By purifying kisspeptins from placenta, it was 
observed that they acted as high potency agonists for KISS1R (60, 62). Similar to its 
ligand, KISS1R was found to abundant in placenta, pituitary, spinal cord and pancreas, 
with lower levels in other brain regions, stomach, small intestine, spleen, lung, testis, 
kidney and breast (60-63). 
Kisspeptins have a single high affinity binding site on KISS1R and all kisspeptins 
bind with similar potencies and affinities (60, 62-64). The EC50 values being 5.47 ± 0.03 
nM, 7.22 ± 0.07 nM, 4.62 ± 0.02 nM and 4.13 ± nM for KP-54, -14, -13 and -10, 
respectively (60, 62, 63). Although KP-54 could potentially have more bioactivity, due to 
its longer peptide sequence and resistance to enzymatic degradation and breakdown (65), 
other studies have shown that all kisspeptins exhibit similar affinities (60, 62, 63).  KD 
values were 1.45 ± 0.1, 1.65 ± 0.15, 4.23 ± 0.1 and 2.33 ± 0.13 nM, respectively, for 




Figure 1.3. Kisspeptins (KPs). Cleavage of kisspeptin-145 results in the production of 












1.3.3 Kisspeptin/KISS1R Signaling 
 KISS1R is a GPCR and signals via Gαq/11 to activate primary effector 
phospholipase C (PLC).  PLC catalyzes the hydrolysis of phosphatidylinositol-(4,5)-
bisphosphate (PIP2) to form inositol-(1,4,5)-trisphosphate (IP3) and diacylglycerol 
(DAG).  IP3 release into the cytoplasm causes an increase in intracellular calcium 
concentration as calcium is mobilized from its internal stores; whereas DAG activates 
protein kinase C (PKC) and MAP kinases extracellular signal regulated kinases (ERK1 
and ERK2) (59, 66).  Additionally, Kotani and colleagues reported an increase in 
arachidonic acid release upon KP-10 induced activation of KISS1R (62) (Figure 1.4).   
GPCR signaling and activity can also be regulated by receptor desensitization, 
internalization and degradation.  Desensitization of GPCRs requires coordination from 
two families of proteins: GPCR serine/threonine kinases (GRKs) and β-arrestins.  Once a 
GPCR binds its ligand, it adopts a conformation that allows GRKs to bind and 
phosphorylate residues on the intracellular loops and carboxy terminus of the receptor.  
This phosphorylation promotes β-arrestin binding which blocks all further coupling of G-
proteins to the GPCR and therefore attenuating receptor signaling (50). KISS1R has been 
shown to be associated with GRK2 and β-arrestin-1 and -2 in human embryonic kidney 
(HEK) 293 cells (67).  Additionally, GRK2 is able to desensitize KP-10-dependent 
KISS1R signaling in HEK 293 cells and β-arrestin-2 has been shown to be required for 
agonist dependent KISS1R-induced ERK1/2 activation in the highly aggressive human 
breast cancer cell line MDA-MB-231 (67).  β-arrestins can also target GPCRs for 
internalization in clathrin-coated vesicles for endocytosis, and then the GPCRs are sorted 
for destruction in the lysosome or recycling back to the cell membrane to allow further 
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signaling (66).  Interestingly, in HEK 293 cells, KISS1R became internalized in a KP-10-
dependent, as well as KP-10-indepdendent manner (67). Although KISS1R displayed a 
high rate of basal internalization, the rate of KP-10-dependent internalization was 
significantly greater than the basal rate (67).  Furthermore, KISS1R was persistently 
expressed at the membrane, even after KP-10 stimulation, and does not co-localize with 
lysosomal markers, indicating ligand-induced KISS1R internalization does not result in 
lysosomal degradation (68).  This dynamic recycling, as opposed to lysosomal 
degradation, and KP-10-independent KISS1R internalization allows for prolonged 
















Figure 1.4 KISS1R signaling pathways. KISS1R signals via a Gαq/11-mediated 
pathway, resulting in activation of phospholipase C (PLC), which leads to an increase in 
phosphotidylinositol-(4,5)-bisphosphate (PIP2) causing subsequent calcium mobilization 
and protein kinase C (PKC) activation. Other downstream effectors include mitogen-
activated protein kinases (MAPKs), extracellular signal regulated kinases (ERK 1/2), 









1.3.4 Physiological Roles of Kisspeptin Signaling 
The kisspeptin/KISS1R system plays an essential role in regulating the 
reproductive axis and initiation of puberty.  Kotani and colleagues first demonstrated 
kisspeptin signaling as an endocrine regulator by showing intravenous administration of 
kisspeptins lead to oxytocin release in rats (69).  Soon after, two independent groups 
revealed that patients with loss-of-function mutations in KISS1R suffer from idiopathic 
hypogonadotropic hypogonadism (IHH) (70, 71).  Patients with IHH have defects in adult 
sexual maturation and are infertile due to the deficiency of the pituitary to secrete 
gonadotropins: follicle-stimulating hormone (FSH) and luteinizing hormone (LH).  These 
patients, however, exhibit normal responsiveness when administered exogenous 
gonadotropin-release hormone (GnRH), suggesting a role for KISS1R in the positive 
regulation of GnRH synthesis or secretion (70).  Similarly, mice deficient of KISS1R 
displayed no sexual development and low circulating concentrations of gonadotropins, 
implicating KISS1R as a major regulator of the neuroendocrine-reproductive axis in 
humans and mice (70).  Female rats injected with the KISS1R antagonist P-234 displayed 
delayed pubertal onset and decreased uterine and ovarian weights at the time of expected 
puberty (72).  Finally, P-234 administration lead to decreased circulating levels of LH 
and FSH (72).  It is now clear that kisspeptins are secreted from the arcuate nucleus of the 
hypothalamus and signal via KISS1R in the median eminence to cause GnRH release.  
Pulsatile GnRH secretion then acts on the pituitary to synthesize and secrete FSH and LH 
(73, 74).  These studies clearly implicated the kisspeptin/KISS1R signaling system as a 
major regulator of sexual maturity and GnRH secretion in humans as well as other 
mammals.   
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In addition to the role in puberty, kisspeptin signaling through KISS1R regulates 
placentation. High expression of KISS1 and KISS1R mRNA has been reported in the 
human placenta, suggesting a role in pregnancy (55, 60-62).  Circulating plasma 
kisspeptin (KP-54) concentrations are low in non-pregnant and non-pubertal individuals 
(1.31 ± 0.37 fmol/mL) (75).  During the first trimester of pregnancy, circulating plasma 
KP-54 concentrations are increased approximately 1000 fold (1230 ± 346 fmol/mL), and 
increase a further 10000 fold (9590 ± 1640 fmol/mL) during the third trimester (69, 75).  
These high kisspeptin levels drop back to non-pregnant concentrations five days post 
partum, indicating the placenta might be a source for these peptides (75).  In vitro assays 
revealed that, KISS1 expression was decreased in first trimester trophoblast compared to 
noninvasive term trophoblast, and KP-54 stimulation was able to block explant invasion 
of trophoblasts by decreasing the protease activity of matrix MMP-2 (76). Along with 
playing a role in trophoblast migration, kisspeptin signaling may also regulate 
placentation by reducing vascularization.  In a placental artery ex vivo angiogenesis 
model, KP-10 significantly reduced total vessel sprouting from the placental artery (77).    
1.3.5 Kisspeptin Signaling in Cancer 
Lee and colleagues originally identified kisspeptins in 1996 as having anti-
metastatic roles in melanoma cells (55).  Since then, decreased function of the 
kisspeptin/KISS1R system has been correlated with cancer progression and increased 
metastasis in pancreatic (78), bladder (79), liver (80), esophageal (81), gastrointestinal 
(82), ovarian (83), thyroid (84)  and endometrial (85) carcinomas (reviewed, (66)).  In 
these cancers, KISS1 and/or KISS1R expression was found to decrease in cancer cells or 
tumour tissue compared to non-malignant tissue and this was found to correlate with poor 
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prognosis in patients.  The anti-metastatic role of kisspeptins was first reported when it 
was discovered that KISS1 gene expression was high in non-metastatic, compared to 
metastatic melanoma cell lines (55).  Another study demonstrated KISS1R-transfected 
B16-BL6 mouse melanoma cells stimulated with kisspeptin, had increased focal 
adhesions and stress fibres in vitro, and had decreased metastasized pulmonary tumour 
foci when injected into the footpads of mice, compared to vehicle controls (60).  To 
examine the role of kisspeptin signaling in pancreatic cancers, Liang and colleagues 
induced pancreatic cancer in Sprague-Dawley rats and measured KISS1 expression.  
Pancreatic tumour tissue exhibited decreased KISS1 mRNA compared to adjacent 
pancreatic tissue (78).  Similar results were seen for bladder cancer, where loss of KISS1 
expression correlates with increased cancer progression (79).  In esophageal, liver, 
gastrointestinal, ovarian, thyroid and endometrial carcinomas, real-time PCR was 
performed on primary tissue samples revealing that low KISS1 and KISS1R correlates 
with the occurrence of aggressive tumours and poor patient prognosis (80-85).   
1.3.6 Kisspeptin Signaling in Breast Cancer Metastasis 
Although kisspeptin signaling has beneficial metastasis suppression activity in 
many cancers, studies by our group and others have reported that the kisspeptin/KISS1R 
system may have detrimental roles in breast cancer (reviewed, (66)).  Martin and 
colleagues first demonstrated that KISS1 mRNA was increased in primary breast 
tumours, compared to background, and KISS1 expression correlated with increased 
tumour grade.  KISS1R mRNA expression, however, was not significantly different 
between breast tumors compared to non-malignant tissue or lymph node positive 
compared to lymph node negative breast tumors (86).  Additionally, KISS1 was higher in 
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patients who had died from breast cancer, than those that remained healthy, suggesting 
KISS1 is correlated with poor breast cancer patient prognosis (86).  In vitro studies 
revealed that upon insertion of KISS1 into MDA-MB-231 cells, the breast cancer cells 
became more motile and invasive (86).  These results were in contrast to previous 
findings of kisspeptin signaling acting as a metastasis suppressor in cancer. 
KISS1 mRNA expression has been shown to be regulated by estradiol (E2), in the 
rat hypothalamus (87).  In breast cancer cells, Marot and colleagues showed that ERα 
negatively regulated KISS1 expression (88). ERα-negative MDA-MB-231 cells were 
transfected to express ERα and upon E2 treatment, KISS1 mRNA expression was shown 
to decrease (88).  Also, ERα-positive human breast cancer cells MCF-7 and T47D, which 
endogenously express low levels of KISS1, displayed increased KISS1 expression upon 
treatment with the ERα antagonist, tamoxifen, again suggesting that E2 signaling via ERα 
negatively regulates KISS1 mRNA expression (88).  This study also revealed that when 
post-menopausal women with ERα-positive tumours were treated with tamoxifen, 
patients with elevated KISS1 and KISS1R mRNA had poorest prognosis compared to 
patients with low levels of KISS1 and KISS1R mRNA (88).  Moreover, KISS1 mRNA 
expression was found to increase with breast tumor grade (88).  This study suggested that 
breast tumour expression of KISS1 and KISS1R mRNA may be a marker for tumoral 
resistance to anti-estrogen treatment.  
The pro-metastasis role of mouse KISS1R signaling was demonstrated in vivo 
using a mouse mammary tumour virus-polyoma virus middle T antigen (MMTV-PyMT) 
mouse model (89).   In 2011, Cho and colleagues generated a Kiss1r haploinsufficient 
MMTV-PyMT mouse model to investigate the effects of KISS1R expression on breast 
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cancer establishment and metastasis.  Although Kiss1- and Kiss1r-knockout mice 
displayed defective pubertal development, heterozygosity of Kiss1/Kiss1r did not result 
in any sexual developmental delays, and therefore was a good model to investigate the 
relationship between mouse Kiss1R signaling and breast cancer metastasis (89).  In this 
study, the decreased Kiss1r expression seen in the heterozygotic PyMT-Kiss1r+/− mice 
attenuated breast tumor initiation, growth, latency, multiplicity and metastasis compared 
to the homozygotic PyMT-Kiss1r+/+ mice (89).  Additionally, primary breast cancer cells 
were isolated from the PyMT-Kiss1r+/− and PyMT-Kiss1r+/+ mice and orthotopically 
injected into wild-type mice to examine if primary tumour growth was affected by 
decreased KISS1R expression.   Haploinsufficient PyMT-Kiss1r+/− cells displayed 
decreased primary breast tumour growth.  Interestingly, decreased Kiss1r expression also 
correlated with a significant reduction in Mmp-9 mRNA implicating Kiss1r as a potential 
regulator of breast cancer invasion (89).  These findings suggest that mouse Kiss1r 
signaling can regulate breast cancer initiation, progression and metastasis. 
Also in 2011, studies from our laboratory demonstrated that KP-10, the shortest 
biologically active kisspeptin, stimulates migration and invasion of ERα-negative human 
breast cancer cells (MDA-MB-231, Hs578T, SKBR3) by transactivating EGFR (90).  We 
found that mechanistically KISS1R signaling stimulated MMP-9 secretion and activity 
and resulted in the activation of EGFR, a β-arrestin 2 dependent pathway.  Moreover, we 
found that KISS1R directly binds EGFR under basal conditions, and this binding 
increases upon KP-10 stimulation (90).  Interestingly, we have demonstrated that the ERα 
status of cells critically dictates the ability of KP-10/KISS1R to induce an invasive 
phenotype.  We have found that KISS1R overexpression, in ERα-negative MCF10A or 
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SKBR3 human breast cancer cells, stimulated an EMT-like event, demonstrated by the 
loss of E-cadherin protein expression in MCF10A cells, and increased protein expression 
of N-cadherin and vimentin in SKBR3 cells.  Furthermore, MCF10A and SKBR3 cells 
overexpressing KISS1R displayed increased cell invasiveness (91).  Interestingly, KP-10 
failed to transactivate EGFR or stimulate invasion in ERα-positive MCF7 or T47D breast 
cancer cells (91) (Figure 1.5).  We found that ERα negatively regulated KISS1R 
expression and function (91). Overexpression of KISS1R in SKBR3 cells also induced 
extravasation using the chick cholioallantoic membrane (CAM) assay (91).  Interestingly, 
KP-10 does not activate other members of the EGFR family, such as HER-2 (unpublished 
data).  Lastly, we found that IQGAP, an actin-binding scaffold protein, was discovered to 
be a binding partner of KISS1R and both proteins localized at the leading edge of 
migrating cancer cells (91).  Although the role of KISS1R in cancer cell invasion, 
migration and metastasis has been investigated, to date, it is unknown whether the 
kisspeptin/KISS1R system regulates breast cancer drug resistance, and thus is the focus 











Figure 1.5. Kisspeptin/KISS1R signaling system in breast cancer.  KISS1R signaling 
can lead to epidermal growth factor (EGFR) activation via β-arrestin 2-dependent 
pathway.  Kisspeptin/KISS1R signaling can stimulate epithelial to mesenchymal 
transition (EMT), and increase matrix metalloporteinases-9 (MMP-9) expression and 





1.4 EGFR Signaling in Breast Cancer 
EGFR (ErbB1) is a member of the EGF receptor family of receptor tyrosine 
kinases, other members include: HER-2 (ErbB2), HER-3 (ErbB3) and HER-4 (ErbB4).  
These receptors consist of an extracellular ligand binding domain, a single hydrophobic 
transmembrane domain and an intracellular domain with protein kinase activity (92).  
Members of the EGF receptor family are ubiquitously expressed in epithelial, 
mesenchymal and neuronal cells and control many important cellular functions including 
proliferation, survival, motility and differentiation (93).  Physiological activation of these 
receptors includes ligand binding which triggers homo- or heterodimerization of EGFR 
with another ErbB receptor family member, most commonly HER-2.  This dimerization 
leads to autophosphorylation of tyrosine residues on the intracellular domain, allowing 
for interactions to be made with downstream molecules and initiation of signal 
transduction (94).   
While EGFR signaling is essential for many normal cellular processes, atypical 
activity of the receptor has been shown to promote tumourigenesis (93).  In fact, EGFR 
was the first receptor studied demonstrating that receptor overexpression can lead to 
cancer (95).  In cancer, EGFR is a key regulator of cell proliferation, tumorigenesis, and 
is an essential driving force for the aggressive growth behaviour of cancer cells (96). 
EGFR is essential for normal breast development, as mice with EGFR mutations 
had impaired mammary gland development (97). Interestingly, EGFR is frequently 
overexpressed in highly aggressive TNBCs (10, 20-22).  Increased EGFR expression was 
also found in patients with metastasis, compared to those without (98).  Due to the 
overexpression of EGFR in TNBCs, EGFR has been a primary target in TNBCs.  Current 
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anti-EGFR therapeutics consist of small molecule tyrosine kinase inhibitors (TKI), that 
compete with ATP to bind to the intracellular catalytic domain of EGFR, and anti-EGFR 
monoclonal antibodies, which bind extracellularly and prevent receptor activation (99).  
Unfortunately, limited clinical success has been seen in TNBC patients given EGFR-
targeted monotherapies, where acquired tumour drug resistance is a major obstacle.  
Greater efficacy, however, has been seen when TNBC patients were treated with anti-
EGFR therapies in combination with traditional chemotherapies, including cisplatin and 
carboplatin (100). 
EGFR signaling also regulates cell survival and is thought to induce tumour drug 
resistance (101).  Although the role of EGFR in modulating chemosensitivity has been 
debated, the majority of reports show significant growth inhibition and/or 
chemosensitivity upon EGFR-blockage through TKIs and monoclonal antibodies (101).  
Additionally, EGFR has been shown to have key functional interactions with other RTKs 
(102).  For example, the RTK, AXL, is able to bind EGFR and become transactivated 
following EGFR activation, independent of stimulation by the AXL ligand (103).  This 
crosstalk between EGFR and AXL has been shown to regulate oncogenic signaling and 
even promote resistance to targeted therapies, specifically to anti-EGFR therapies in non-
small cell lung cancer and breast cancer (103, 104). Since we have shown that KISS1R 
can transactivate EGFR, the proposed work investigates if this signaling pathway induces 





1.5 TAM Family of Receptor Tyrosine Kinases 
The TAM (TYRO3, AXL and MER) family of receptor tyrosine kinases share 
similar overall structure and function (105).  TAM RTKs are frequently overexpressed in 
numerous cancers where they promote cell survival and allow for tumour cell growth 
(106).  Little is currently understood about TYRO3 signaling, however, MER and AXL 
have been shown to activate standard proliferative pathways with in the cell, including 
the PI3K/Akt and MAPK/ERK pathways.  This activation of proliferative signaling, 
however, typically promotes cell survival, as opposed to cell proliferation (106). 
1.5.1 AXL Signaling in Cancer 
AXL was originally detected in 1998 from two patients with chronic 
myelogenous leukemias.  Overexpression of AXL has been reported in several human 
cancers including breast, colon, esophageal, thyroid, ovarian, gastric, renal, glioma and 
lung (107, 108).  The oncogenic potential of AXL is due to its tyrosine kinase domain, 
which can be activated independent of ligand binding through overexpression, or by 
binding of its ligand, growth arrest-specific gene 6 (Gas-6) (109).  Using a xenograft 
orthotopic breast tumour model, primary tumour growth was decreased when MDA-MB-
231 had decreased AXL expression due to RNAi knock down (110).  Similar results were 
found in vitro, when RNAi specific knockdown of AXL decreased breast cancer cell 
invasion (111).  Since then, it has been discovered that AXL signals via downstream 
phosphorylation of Akt and ERK1/2 in order to protect cells from apoptosis, as well as 
increase migration and growth (111).  Inhibition of AXL can block Akt/ERK pathways, 
however, complete inactivation of AXL requires simultaneous inhibition of other receptor 
tyrosine kinases, including EGFR, indicating a crosstalk between EGFR and AXL (103).  
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Specifically, it has been shown that EGFR transactivation of AXL in TNBC cells can 
lead to increased downstream signaling, inducing a invasive phenotype, one that is not 
primarily activated by EGFR itself (108).  Recent studies have reported that AXL may 
also promote drug resistance in a number of cancers.  Overexpression of AXL has been 
linked to imatinib resistance, a TKI, in gastrointestinal stromal tumours (112).  AXL 
overexpression has been associated with resistance to conventional chemotherapies as 
well as targeted therapies in a number of other cancers, including acute myeloid 
leukemia, lung, ovarian, and breast (113-115).   
1.5.2 AXL and Breast Cancer Drug Resistance 
The role that AXL plays in breast cancer drug resistance is currently under 
investigation.  Thus far, in TNBC, AXL has been specifically linked to resistance of 
EGFR-targeted therapies (116).  Additionally, shRNA-mediated depletion of MER, 
another member of the TAM receptor tyrosine kinase family, resulted in a reduction of 
prosurvival proteins known to play roles in chemoresistance, including survivin (114).  
Another study found that chronic exposure of breast cancer cells, which endogenously do 
not express AXL, to lapatinib, a TKI currently being used clinically to treat breast 
tumours, caused lapatinib resistance as well as de novo AXL expression.  Surprisingly, 
upon AXL depletion via AXL-targeted siRNA, sensitivity to lapatinib was restored (117).   
Interestingly, in TNBC MDA-MB-231 cells, EGFR has been shown to 
transactivate AXL, in a Gas-6-independent manner (103).  This transactivation could 
potentially lead to a diversified downstream signaling cascade that is beyond that 
produced by EGFR activation and signaling alone (103).  Additionally in TNBC cells, 
AXL and EGFR are overexpressed, and through immunoprepiciptation experiments, the 
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two receptors have been shown to physically interact (103).  A similar study 
demonstrated that EGFR activation, upon EGF stimulation in MDA-MB-231 cells, led to 
phosphorylation of AXL; however, EGFR was not phosphorylated when AXL was 
stimulated by Gas-6 (118).  Recently, AXL has also been shown to stimulate EMT in 
breast cancer cells, and EMT has been shown to correlate with acquired resistance in 
many cancers (108, 118).  Depletion of AXL, through shRNA, was shown to decrease 
markers of EMT, including vimentin and Snail-Slug in breast cancer cells (118).  
Similarly, cells treated with an AXL inhibitor, reversed the EMT phenotype and became 
more sensitive to paclitaxel (118).   
Since AXL has been implicated in regulating breast cancer metastasis as well as 
drug resistance, the discovery and targeting of upstream regulators of AXL would 
potentially decrease two of the current major problems with treating TNBC.  Whether 











1.6 Rationale, Objectives and Hypothesis 
1.6.1 Rationale 
KISS1 expression increases in human tumour tissue compared to healthy 
mammary tissue and this increase correlates positively with an increase in breast tumour 
grade (86).  Additionally, breast cancer patients with high KISS1 and KISS1R mRNA 
were associated with shortest relapse-free survival (88).  Our laboratory has previously 
shown that KISS1R signaling stimulates ERα-negative breast cancer cell invasion and 
migration by transactivating EGFR (90).  However, whether KISS1R regulates EGFR 
expression and if this signaling pathway regulates drug resistance in ERα-negative breast 
cancer cells is unknown and will be investigated here.   
 
1.6.2 Hypothesis 
In ERα-negative human breast cancer cells, KISS1R signaling promotes EGFR 
expression and drug resistance.  
 
1.6.3 Objectives 
To determine whether: 
1) In ERα-negative breast cancer cells KISS1R signaling induces EGFR expression 
2) KISS1R signaling stimulates breast cancer drug resistance and to identify the 
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2.1 Materials and Methods 
 
Human Cell Culture: All human breast cancer cells were purchased from ATTC 
(Manassas, VA).  Characteristics of cell lines are shown in Table 2.1. Cells were 
maintained at 37 ˚C with 5% CO2.  MCF10A cells were grown in mammary epithelial 
basal medium (MEBM; Clonetics-Cambrex, Walkersville, MD) supplemented with a 
MEGM Single Quots kit (bovine pituitary extract, human epidermal growth factor, 
insulin, hydrocortisone, gentamicin/amphotericin) and cholera toxin (100 ng/mL).  
SKBR3 and MDA-MB-231 were cultured in Rosswell Park Memorial Institute 1640 
(RPMI 1640) (Invitrogen, Burlington, ON) supplemented with 10% (v/v) fetal bovine 
serum (FBS) (Sigma-Aldrich, Oakville, ON).  All stable cell lines generated (MCF10A 
FLAGKISS1R and SKBR3 FLAGKISS1R) represent polyclonal cell populations as 












Table 2.1. Summary of the human cell culture models used in the study. 
Cell Lines Characteristics of the Parental Cell Line 
Human Mammary Epithelial Cells 
MCF10A 
Derivatives: 
! MCF10A pFLAG 
! MCF10A FLAGKISS1R (1) 
 
! Non-malignant mammary epithelial cells isolated 
from patient with fibrocystic disease (2) 
 
! Non-motile and non-invasive (2) 
 
! ERα-negative (3) 
 
! Endogenously express KISS1R (1) 
 
! Overexpression of KISS1R stimulates EMT-like 
phenotype and cell invasion (1) 
Human Breast Cancer Cells 
SKBR3 
Derivatives: 
! SKBR3 pFLAG 
! SKBR3 FLAGKISS1R (1) 
 
! Weakly invasive, isolated from pleural effusion of 
patient (4) 
 
! ERα-negative (5) 
 
! HER-2 overexpressing breast adenocarcinoma (5) 
 
! Very low endogenous expression of KISS1R (1) 
 
! Overexpression of KISS1R stimulated 
mesenchymal marker expression and tumour cell 
extravasation in vivo (1) 
MDA-MB-231 
 
! Highly invasive breast adenocarcinoma (6) 
 
! ERα-negative (6) 
 







Stable Transfections: FLAGKISS1R and pFLAG (vector control) constructs were 
generated as described (8) and obtained from Dr. Andy Babwah.  MCF10A and SKBR3 
cells (1 X 106 cells) were transfected with 5 µg cDNA constructs by microporation 
(1700V, 10 pulse width, 3#) using the NeonTM Transfection System (Invitrogen) 
according to the manufacturer’s instructions.  A heterogeneous population of stable 
transfectants was selected by using media containing 750 µg/mL G418 (Invitrogen) as 
described (1).  Stable heterogeneous populations of cells were maintained in media 
containing G418 (1.5 ng/mL) and expression of proteins was verified weekly by Western 
blot analysis. 
 
Immunofluorescence Microscopy: SKBR3 cells expressing pFLAG or FLAGKISS1R 
were immunostained as previously described (1, 9).  Briefly, SKBR3 cells were washed 
with Hank’s Balanced Salt Solution (HBSS), fixed and permeabilized with 4% 
paraformaldehyde (0.2% Triton-X) at room temperature for 20 minutes.  Phalloidin 
(1:100, Invitrogen) conjugated to Alexa Fluor 555 was incubated for 1 hour to visualize 
F-actin stress fibers.  Nuclei were stained with 0.01% Hoechst 33258 (Invitrogen) or 
Sytox Green (Invitrogen). Images were acquired using an LSM-510 META laser-
scanning microscope (Zeiss, Oberkochen, Germany).  
 
Immunoblot Assays: Experiments were performed as previously described (1, 9).  
MCF10A, SKBR3 and MDA-MB-231 cells were lysed using RIPA buffer (150 mM 
NaCl, 50 mM Tris pH8, 5 mM EDTA, 1% NP40, 0.1% SDS, 10 mM NaF, 0.5% 
deoxycholate, 10 mM sodium pyrophosphate, protease inhibitors).  Protein (50 µg or 100 
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µg) was separated by SDS-PAGE and expression was examined using antibodies raised 
against human proteins: rabbit anti-KISS1R (1:2000, Abcam, Toronto, ON), mouse anti-
BCRP (1:150, Abcam), mouse anti-MRP1 (1:750, Abcam), rat anti-MRP4 (1:1000, 
Abcam), rabbit anti-AXL (1:1000, Cell Signaling, Whitby, ON), rabbit anti-Snail-Slug 
(1:500, Santa Cruz, Dallas, TX), rabbit anti-vimentin (1:500, Cell Signaling), rabbit anti-
ERK (1:1000, Cell Signaling), rabbit anti-phoshpo-ERK1/2 (1:2000, Cell Signaling), 
rabbit anti-Akt (1:1000, Abcam), rabbit anti-phospho-Akt (1:1000, Abcam), rabbit anti-
survivin (1:1000, ThermoScientific, Burlington, ON), rabbit anti-SP-1 (1:1000, Millipore, 
Billurica, MA) or rabbit anti-NF-κB (1:1000, Millipore).  Rabbit (1:2500, GE Healthcare 
UK, Buckinghamshire, UK), mouse (1:2500, GE Healthcare UK) and rat (1:10000, 
Invitrogen) secondary antibodies conjugated to horseradish peroxidase were used to 
visualize chemiluminescence. β-actin (anti-rabbit polyclonal, 1:2000, Sigma-Aldrich) 
expression was used as a loading control. 
 
Scratch Assays for Cell Motility: SKBR3 cells expressing pFLAG or FLAGKISS1R 
were seeded into a 12-well dish in RPMI and grown to 100% confluence.  Cells were 
then serum starved, grown in media without FBS, for 24-hours and scratched with a 
sterile pipette tip before being left in serum free media or FBS supplemented media as 
previously described (1, 9).  Cells were allowed to migrate into the scratch for 24 hours.  
Cells were imaged every 15 minutes using an automated Olympus IX-81 microscope.  
Distance travelled was measured at seven random locations per well, and wells were 
analyzed in duplicates.  This analysis was performed using ImagePro software (Media 
Cybernetics, Rockville, MD).   
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Doxorubicin Accumulation Assay: SKBR3 pFLAG and SKBR3 FLAGKISS1R cells 
were treated with 1 µM of doxorubicin for 2 hours as previously described (10).  Cells 
were then fixed with 4% paraformaldehyde at room temperature for 20 minutes and 
washed with HBSS.  Nuclei were then stained with 0.01% Hoechst 33258 (Invitrogen).  
Cells were mounted on slides and imaged using an LSM-510 META laser scanning 
microscope using a Zeiss 63X objective, oil immersion lens.  
 
MTT Cell Viability Assay: MTT cell viability assays were conducted as previously 
described (11) and according to manufacturer’s instruction (Cell Signaling).  Briefly, 7.5 
x 104 cells (MCF10A pFLAG, MCF10A FLAGKISS1R, SKBR3 pFLAG, SKBR3 
FLAGKISS1R and MDA-MB-231) were plated in a 96-well plate and stimulated with 1 
µM P-234 or left untreated overnight in media containing 10% FBS.  Prior to doxorubicin 
treatment, cells were pretreated for 10 minutes with 50 µM MK-571, or a cocktail of drug 
efflux transporter inhibitors (50 µM MK-571, 10 µM FTC, 1 µM LY-335979), to inhibit 
MRPs, BCRP and P-gp, respectively, or with vehicle control.  A dose response 
experiment was conducted, using graded concentrations of doxorubicin, ranging from 
0.01 µM to 300 µM, for MCF10A and SKBR3 cells or 0.01 µM to 2 mM, for MDA-MB-
231 cells, for 48 hours.  Erlotinib experiments were performed by treating cells for 72 
hours with graded concentrations, ranging from 0.1 µM to 150 µM.  Media was then 
aspirated and cells were incubated with 0.5 mg/mL of MTT labeling (3-(4,5-
dimethylthiazol-2-yl)-2,5-diephenyltetrazolium bromide) agent for 4 h and subsequently 
solubilized with DMSO.  Absorbance of the supernatant was read at 550 nm with a 
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background subtraction at 670 nm, using a Victor3V 1420 Multi Label Counter (Perkin 
Elmer, Waltham, MA). 
 
Cell Growth Assays: To determine cell growth, monolayer cultures of SKBR3 pFLAG 
and SKBR3 FLAGKISS1R cells (5 X 105), were seeded into 60-mm dishes and 
trypsinized at 24, 48 and 72 hours.  The number of cells was determined using a 
hemocytometer as previously described (1, 9).    
 
AXL Depletion by siRNA: SKBR3 FLAGKISS1R cells were grown to 60% confluency 
and transfected with 4 µg of control or AXL siRNA (Ambion, Life Technologies, Austin, 
TX) by jetPRIME reagent, according to manufacture’s instructions (Polyplus 
Transfection, Illkirch, France).  Cells were maintained in FBS supplemented media 
without antibiotics for 48 hours.  Protein expression of AXL in SKBR3 FLAGKISS1R 
cells was determined by Western blot analysis.   
 
EGFR Immunoprecipitation: These experiments were conducted as previously 
described (1, 9).  SKBR3 pFLAG and SKBR3 FLAGKISS1R cells were cultured to 80% 
confluency and serum-starved for 24 hours.  Cells were washed with ice-cold phosphate-
buffered saline (PBS) and lysed in glycerol lysis buffer (20 mM HEPES, 150 mM NaCl, 
1.5 mM MgCl2, 1 mM EDTA, 2 mM Na3VO4, 1 mM NaF, 10% glycerol, 1% Triton X-
100) containing protease inhibitors (1 µL/mL aprotinin, 1 µL/mL leupeptin and 10 
µL/mL AEBSF).  Lysates (500 µg of total protein) was used for immunoprecipitation 
studies. EGFR was immunoprecipitated from total lysates using anti-EGFR antibody (4 
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µg, Millipore), incubated at 4 °C overnight.  Immunoprecipitated proteins were then 
pulled-down with protein G Dynabeads (Life Technologies) and resolved by Western blot 
analysis.  Phosphorylated EGFR was determined using an antiphosphotyrosine antibody 
(PY-20, Santa Cruz) at 1:1000.  Total EGFR was determined using an anti-EGFR 
antibody (1:4000, Millipore).  Densitometric analysis was performed using VersaDoc 
Imaging System (Bio-Rad, Hercules, CA).    
 
Quantitative Reverse Transcription PCR: Total RNA was extracted from SKBR3 
pFLAG, SKBR3 FLAGKISS1R, or MDA-MB-231 cells using RNeasy Mini Kit 
instructions (Qiagen, Venlo, Netherlands) and quantified spectrophotometrically at 
260nm.  Total RNA (1 µg) was used to prepare cDNA.  Reverse-transcription was carried 
out according to manufacturer’s instructions using iScript RT Supermix (Bio-Rad).  To 
investigate the expression of KISS-1, KISS1R, EGFR, AXL, BCRP, MRP1, MRP4 or 
control (GAPDH), real-time quantitative polymerase chain reaction (RT-qPCR) was 
performed using SYBR green methodology. Standard curves for each gene were 
constructed separately using serially diluted reverse-transcription products.  The mRNA 
levels of each gene of interest were determined by amplification of 25 ng of cDNA using 
specific primers (Table 2.2), RNase-free water, and SsoFast EvaGreen Supermix (Bio-
Rad). Results were normalized to GAPDH. RT-qPCR runs were comprised of an initial 
denaturation step, 95°C for 3 min, then 40 cycles at 95 °C for 10 s, and 60 °C for 30 s.  
Experiments were performed in triplicates for each data point.  
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Chromatin immunoprecipitation (ChIP): ChIP was performed on SKBR3 pFLAG and 
SKBR3 FLAGKISS1R cells using EZ-Magna ChIPTM G-Chromatin Immunoprecipitation 
Kit (Millipore) according to the manufacturer’s protocol, with slight modifications.  
Briefly, DNA was cross-linked to protein by treating SKBR3 cells with 1% formaldehyde 
for 20 minutes at room temperature.  Unreacted formaldehyde was then quenched with 
137.5 mM glycine for 5 minutes at room temperature.  Cells were then lysed and 
sonicated to shear DNA to a length of 200 to 1,000 base pairs.  Chromatin samples were 
then incubated overnight at 4 °C with antibodies to SP-1 (4 µg/sample, Millipore), RNA 
polymerase II (RNA Pol II, 2 µg/sample, Millipore) or nonimmune IgG from the same 
host species (anti-rabbit or anti-mouse, Millipore) as well as 20 µL protein G magnetic 
beads.  After overnight incubation, beads were washed, crosslinks were reversed and 
chromatin was eluted with 2-hour Elution Buffer and Proteinase K treatment.  DNA was 
subsequently purified using spin columns.  The binding of SP-1 (-101 to - 88) and RNA 
Pol II to the human EGFR promoter (12) was quantified by RT-qPCR using primers that 










Table 2.2. Summary of the RT-qPCR primers used in this study. 
Gene Primer Sequence 
KISS1 F R 
5’-GGACCTGCCTCTTCTCACCA-3’ 
5’-ATTCTAGCTGCTGGCCTGTG-3’ 
KISS1R F R 
5’-CCCACCCTCTGGACATTCAC-3’ 
5’CCTAGAAGTGCCTTGAGGCTTG-3’ 
AXL F R 
5’-CAGCAAGAGCGATGTGTGGT-3’ 
5’-CGATTTCCCTGGCGCAGATA-3’ 
EGFR F R 
5’-CAACAGCACATTCGACAGCC-3’ 
5’-CTCCGTGGTCATCGTCCAAT-3’ 
MRP1 F R 
5’-CGGAAACCATCCACGACCCTATTC-3’ 
5’-ACCTCCTCATTCGCATCCACCTTG-3’ 
MRP4 F R 
5’-AAGTGAACAACCTCCAGTTCCAG-3’ 
5’-GGCTCTCCAGAGCACCATCT-3’ 
BCRP F R 
5’-TGGCTGTCATGGCTTCAGTA-3’ 
5’-GCCACGTGATTCTTCCACAA-3’ 
GAPDH F R 
5’-TGGTATCGTGGAAGGACTCA-3’ 
5’-TTCAGCTCAGGGATGACCTT-3’ 















Subcellular Fractionation: SKBR3 pFLAG and SKBR3 FLAGKISS1R cells were 
washed with PBS and lysed in RIPA buffer supplemented with protease inhibitors.  
Lysed cells were then pelleted by centrifugation.  Supernatant was collected as the 
cytosolic fraction.  The pellet was then washed with ice-cold PBS and resuspended in 
RIPA buffer.  The resuspended pellet was then sonicated on ice and centrifuged to 
remove any unsolubilized cellular contents.  Total protein was acquired by lysing SKBR3 
cells in RIPA buffer, and sonicating, on ice, the total lysate.  Sonicated lysates were then 
centrifuged at 15,000 g for 20 minutes at 4 ºC, to remove unsolubilized cellular contents. 
Aliquots of cytoplasmic, nuclear and total extracts (50 µg) were used as samples for 
Western immunoblot analysis. 
 
Statistical Analysis: One-way analysis of variance (ANOVA) with a Dunnett’s post-hoc 
test or two-way ANOVA followed by Bonferonni post-hoc test was performed using 
GraphPad Prism 5 (GraphPad Software, Inc).  Differences were considered statistically 




KISS1R overexpression increased mesenchymal phenotype of SKBR3 breast cancer 
cells  
The process of EMT has been shown to be critical in the progression of many 
cancers, including breast (13).  Switching of the cellular phenotype from epithelial to 
mesenchymal requires numerous modifications including a decrease of cell adhesion, 
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morphological changes from cobblestone (epithelial) to spindle (mesenchymal) shape and 
the acquisition of a migratory and invasive phenotype (13).  A defining feature of EMT is 
a loss of E-cadherin, and an increase in expression of mesenchymal cell markers 
including vimentin, N-cadherin and Snail-Slug (14).   
To evaluate the role of KISS1R in breast cancer, we took a gain-of-function 
approach by overexpressing KISS1R in the weakly invasive SKBR3 cells, which 
endogenously express very low levels of KISS1R (1) (Figure 2.1A).   FLAGKISS1R and 
pFLAG (vector control) were stably expressed in SKBR3 cells; these cells represent 
heterogeneous populations of transfectants and have been previously characterized (1).  
SKBR3 FLAGKISS1R cells have increased expression of mesenchymal markers, 
vimentin and N-cadherin, and extravasate in chick embryo chorioallantoic membrane 
(CAM) assays, compared to vector controls (1).   
Western blot analysis of EMT markers in SKBR3 FLAGKISS1R cells verified 
our previous findings that there was an increase in expression of the mesenchymal 
markers vimentin, N-cadherin and Snail-Slug compared to vector controls (Figure 2.1A).  
Similarly, overexpression of KISS1R increased the mesenchymal phenotype of SKBR3 
cells resulting in more spindle shaped morphology, compared to the vector control 
(Figure 2.1B).  SKBR3 FLAGKISS1R cells also had increased actin stress fiber 
formation, often associated with cellular migration (Figure 2.1C).  This data suggests, as 
we’ve already demonstrated (1), that the stable expression of KISS1R in ER-negative 
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Figure 2.1. KISS1R overexpression increased the mesenchymal phenotype of 
SKBR3 breast cancer cells. A) Representative Western blots showing expression levels 
of KISS1R (n=6) and mesenchymal markers vimentin (n=3), N-cadherin (n=3), and 
Snail-Slug (n=3) in SKBR3 pFLAG and SKBR3 FLAGKISS1R cells.  Western blot 
analysis performed with rabbit anti-KISS1R, rabbit anti-vimentin, mouse anti-N-
cadherin, and rabbit anti-Snail-Slug.  Densitometric analysis of Western blot expression 
normalized to β-actin.  Student’s unpaired T-test: *, P<0.05. Columns represent mean 
protein expression ± SEM. B) Representative DIC images of SKBR3 pFLAG (control) or 
SKBR3 FLAGKISS1R (n=3). 40x. Scale Bar, 50µm.  C) F-actin stained with phalloidin- 
Alexa Fluor 555 (red) and nuclei using Sytox Green (green) and visualized by confocal 
microscopy. Images representative of four independent experiments. Scale Bar, 20µm. 
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KISS1R overexpression increased KISS1 mRNA expression in SKBR3 cells 
 KISS1 is the gene encoding for kisspeptin peptides, the ligands for KISS1R (15).  
RT-qPCR was performed in order to determine expression of KISS1R and KISS1 mRNA 
in SKBR3 pFLAG and SKBR3 FLAGKISS1R cells.  SKBR3 FLAGKISS1R cells had 
significantly increased KISS1R mRNA and protein expression, compared to pFLAG 
controls (Figure 2.2).  Interestingly, SKBR3 FLAGKISS1R cells also expressed 
increased KISS1 mRNA (Figure 2.2). This data suggests that KISS1R overexpression 
appears to increase the expression of the gene encoding its own ligand, which may 


















Figure 2.2. KISS1R overexpression increased KISS1 mRNA in SKBR3 cells.  
Relative mRNA expression of KISS1R and KISS1 as identified by RT-qPCR (n=4).  
Student’s unpaired T-test: *, P<0.05. Columns represent mean relative mRNA 

















KISS1R signaling stimulated motility of breast cancer cells. 
Cells that have undergone EMT display enhanced motility (1), a critical process in 
cancer metastasis.  In order to assess if KISS1R expression regulated SKBR3 cell 
motility, scratch assays were performed, as previously described (1, 9). SKBR3 
FLAGKISS1R cells migrated further in comparison to vector control cells (Figure 2.3A).  
To exclude confounding effects of KISS1R overexpression on cell proliferation, cell 
growth assays were performed to determine the doubling time of these cells.  Both 
SKBR3 pFLAG and SKBR3 FLAGKISS1R cells had a doubling time greater than 48 
hours (Figure 2.3B).  Thus, this suggests that the effects of KISS1R overexpression on 
scratch closure was due to the increased cell motility and not because of increased 
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Figure 2.3. Overexpression of KISS1R increased breast cancer cell motility. A) 
KISS1R overexpression in SKBR3 cells increases the distance closed by FLAGKISS1R 
cells compared to pFLAG controls over a 24 hour period (n=3). Cells were allowed to 
migrate in serum-free (SF) or fetal bovine serum (FBS)- supplemented media. Two-way 
ANOVA followed by Bonferroni post-hoc test: a, P<0.05 for pFLAG FBS vs 
FLAGKISS1R FBS; b, P<0.05 for FLAGKISS1R SF vs FLAGKISS1R FBS; c, P<0.05 
for FLAGKISS1R SF vs pFLAG SF. Scale Bar, 100µm. B) SKBR3 pFLAG and SKBR3 
FLAGKISS1R cells were cultured for 72 hours with or without 100 nM KP-10 and 
counted at 24 hour intervals (n=3). Two-way ANOVA followed by Bonferroni post-hoc 
test: a, P<0.05 for pFLAG compared to FLAGKISS1R; b, P<0.05 for pFLAG+KP10 





KISS1R signaling increased endogenous EGFR protein and mRNA expression  
Previously, we have demonstrated that KISS1R promotes the invasion of ERα-
negative breast cancer cells, MDA-MB-231 and Hs578T, by activating EGFR (1, 9).  We 
next sought to determine if KISS1R regulates EGFR expression in KISS1R 
overexpressing cells.  Thus, EGFR protein and mRNA expression was examined in 
SKBR3 cells overexpressing KISS1R.  SKBR3 FLAGKISS1R cells had in an increase in 
total endogenous EGFR protein, although the relative amount of active EGFR did not 
appear to increase with KISS1R overexpression, compared to pFLAG control cells 
(Figure 2.4A).  EGFR mRNA expression also increased in SKBR3 FLAGKISS1R cells 
compared to SKBR3 pFLAG cells.  Interestingly, in SKBR3 FLAGKISS1R as well as 
MDA-MB-231 cells, EGFR mRNA expression decreased upon treatment of cells with 
KISS1R antagonist, P-234 (Figure 2.4B-C).  Therefore, this data suggests that KISS1R 
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Figure 2.4. KISS1R overexpression and signaling increased endogenous EGFR 
expression. A) Representative Western blots showing overexpression of KISS1R in 
SKBR3 breast cancer cells resulted in increased endogenous EGFR expression (n=6).  
Phosphorylated (active) EGFR (PY20) was also examined in pFLAG and FLAGKISS1R 
cells (n=3).  Densitometric analysis of Western blot expression was normalized to β-
actin.  B) EGFR mRNA in SKBR3 pFLAG and FLAGKISS1R cells analyzed by RT-
qPCR. SKBR3 pFLAG and FLAGKISS1R cells were serum-starved for 48 hours with 
the presence of 1 µM P-234 or 20% acetonitrile vehicle control (VEH) (n=3). Two-way 
ANOVA followed by Bonferroni post-hoc test: a, P<0.05 for pFLAG VEH vs 
FLAGKISS1R VEH; b, P<0.05 for FLAGKISS1R VEH vs FLAGKISS1R P-234; c, 
P<0.05 for FLAGKISS1R P-234 vs pFLAG P-234. C) EGFR mRNA in MDA-MB-231 
cells. Cells were serum-starved for 48 hours in the presence of 1 µM P-234 or vehicle 
control.  Total RNA was isolated and RT-qPCR was performed using primers for EGFR 
and GAPDH (n=3). One-way ANOVA followed by Dunnet’s multiple comparison test; 




KISS1R overexpression increased nuclear expression of SP-1 and NF-κB 
To better understand how KISS1R signaling increases EGFR mRNA and protein 
expression, subcellular fractionation was performed in SKBR3 pFLAG and SKBR3 
FLAGKISS1R cells.  The location and expression of the transcription factors SP-1 and 
NF-κB, both of which are known to positively regulate EGFR expression, was examined 
(16, 17).  There was an enrichment of SP-1 in the nuclear fraction of SKBR3 
FLAGKISS1R cells compared to pFLAG control cells, as demonstrated by Western blot 
analysis (Figure 2.5A).  Similarly, NF-κB expression in the nuclear fraction was also 
increased upon in SKBR3 FLAGKISS1R cells (Figure 2.5B). Histone H3 and HSP90 
were used nuclear and cytosolic markers, respectively (18, 19).  This data suggests that 
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Figure 2.5. KISS1R overexpression increased nuclear expression of SP-1 and NF-κB 
in SKBR3 breast cancer cells.  Western blot showing overexpression of KISS1R in 
SKBR3 cells increases expression of (A) SP-1 and (B) NF-κB in the nuclear fraction.  
Protein was isolated from cytosolic and nuclear fractions from SKBR3 pFLAG and 
SKBR3 FLAGKISS1R cells.  Western blot analysis performed with anti-human rabbit 
anti-SP-1 and mouse anti-NF-κB. Mouse anti-Histone H3 and rabbit anti-HSP90 were 
used as nuclear and cytosolic markers, respectively.  Densitometric analysis of Western 
blot expression normalized to Histone H3 (n=3).  Student’s unpaired T-test: *, P<0.05. 








KISS1R overexpression increased nuclear recruitment of SP-1 to the EGFR promoter 
To determine if increased SP-1 nuclear expression was a potential mechanism by 
which KISS1R signaling up-regulates EGFR expression, we performed chromatin 
immunoprecipitation (ChIP) on SKBR3 pFLAG and SKBR3 FLAGKISS1R cells.  
Binding of SP-1 to the EGFR promoter was significantly increased 2-fold in 
FLAGKISS1R cells compared to pFLAG control cells (Figure 2.6A).  Recruitment of 
RNA Pol II to the EGFR promoter was also increased 2-fold (Figure 2.6B).  This data 
suggests that increased EGFR expression in SKBR3 FLAGKISS1R cells may be due to 
increased nuclear protein expression of SP-1 and also binding of SP-1 to the EGFR 
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Figure 2.6. KISS1R overexpression increased SP-1 and RNA Pol II recruitment to 
the EGFR promoter. A) SP-1 binding and B) RNA Pol II binding to the EGFR 
promoter, to the most proximal of SP-1 binding sites to the transcriptional start site.  
ChIP was performed on SKBR3 pFLAG and SKBR3 FLAGKISS1R cells using an anti 
SP-1-specific or RNA Pol II-specific antibody.  Relative binding of SP-1 or RNA Pol II 
is expressed as a percentage of pFLAG control binding.  SKBR3 pFLAG control cells 
were arbitrarily defined as 100% (n=3).  One-way ANOVA followed by Dunnet’s 
multiple comparison test: *, P<0.05 .  Columns represent mean relative SP-1 or RNA Pol 










KISS1R overexpression inhibited doxorubicin accumulation 
The ability of cancer cells to become resistant to chemotherapies makes treatment 
difficult, resulting in poor patient outcome (20).  Since KISS1R positively regulates 
EGFR, and EGFR has been shown to increase cancer cell survival and drug resistance, 
we next sought to determine if KISS1R regulated drug resistance as well (20).  In order to 
determine a role for KISS1R in the regulation of drug resistance, we first examined the 
effect of KISS1R overexpression in SKBR3 cells on intracellular accumulation of the 
chemotherapeutic, doxorubicin.  SKBR3 pFLAG and SKBR3 FLAGKISS1R cells were 
treated with doxorubicin and intracellular drug accumulation was assessed.  Doxorubicin 
is a traditional chemotherapy, which autofluoresces red, thus allowing a simple 
assessment of intracellular drug concentrations (21).  We observed that doxorubicin 
accumulation in SKBR3 FLAGKISS1R cells was decreased, compared to the vector 
control cells (Figure 2.7).  These results indicate that KISS1R expression may regulate 












Figure 2.7. KISS1R overexpression inhibited doxorubicin accumulation in SKBR3 
breast cancer cells.  Representative confocal images showing intracellular doxorubicin 
fluorescence (red) in SKBR3 vector controls (top) and SKBR3 FLAGKISS1R cells 
(bottom).  Cells were treated with 1 µM doxorubicin, for 2 hours and accumulation was 
visualized by confocal microscopy.  Scale bars, 20 µm. Hoechst was used as a nuclear 











KISS1R overexpression stimulated the expression of drug efflux transporters 
Doxorubicin has been shown to be a substrate for drug efflux transporters BCRP, 
MRP1 and MRP4, and overexpression of these efflux transporters has been associated 
with increased cellular resistance (22).  Since we observed decreased doxorubicin 
accumulation in SKBR3 FLAGKISS1R cells, we next investigated the expression of drug 
efflux transporters by Western blot analysis and RT-qPCR.   Overexpression of KISS1R 
in SKBR3 cells significantly increased expression of BCRP, MRP1 and MRP4 compared 
to controls (Figure 2.8A).  We also found a significant increase in BCRP mRNA in 
SKBR3 FLAGKISS1R cells compared to controls, however, no change in mRNA levels 
were observed for MRP1 or MRP4, upon overexpression of KISS1R (Figure 2.8B).  
Interestingly, treating SKBR3 FLAGKISS1R or MDA-MB-231 cell with P-234, a 
KISS1R antagonist, resulted in lower levels of BCRP mRNA, compared to cells treated 
with the vehicle control (Figure 2.9).  P-234 treatment of SKBR3 FLAGKISS1R cells 
did not, however, decrease MRP1 mRNA expression (Supplementary Figure 3).  This 
data suggests that KISS1R positively regulates the expression of drug efflux transporters, 
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Figure 2.8. KISS1R overexpression increased endogenous levels of drug efflux 
transporters in SKBR3 cells. A) Representative Western blots showing expression 
levels of BCRP, MRP4, MRP1 in SKBR3 pFLAG and SKBR3 FLAGKISS1R cells (n=3-
5).  Western blot analysis performed with mouse anti-BCRP, rat anti-MRP4 and mouse 
anti-MRP1. Densitometric analysis of Western blot expression normalized to β-actin. 
Student’s unpaired T-test: *, P<0.05. Columns represent mean protein expression ± SEM.   
B) BCRP, MRP4, and MRP1 mRNA expression in SKBR3 pFLAG and SKBR3 
FLAGKISS1R cells. Total RNA was isolated from SKBR3 cells and RT-qPCR was 
performed using primers for BCRP, MRP4, MRP1 and GAPDH (n=5).  Student’s 
unpaired T-test: *, P<0.05. Columns represent mean relative mRNA expression, 
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Figure 2.9. P-234 pretreatment decreased BCRP mRNA expression in breast cancer 
cells. BCRP mRNA expression in (A) SKBR3 cells overexpressing KISS1R and (B) 
MDA-MB-231 cells. Cells were treated with 1 µM P-234 or vehicle control (VEH) in 
serum-free conditions for 48 hours.  Total RNA was isolated from SKBR3 cells and RT-
qPCR was performed using primers for BCRP and GAPDH (n=3). Student’s unpaired T-
test: *, P<0.05. Columns represent mean relative mRNA expression, normalized to 














KISS1R signaling promoted drug resistance 
To further evaluate if KISS1R signaling promotes chemoresistance, MTT cell 
viability assays were conducted in the presence of graded concentrations of doxorubicin 
for 48 hours (23).  We found that SKBR3 FLAGKISS1R cells displayed increased cell 
survival in the presence of doxorubicin, compared to SKBR3 pFLAG cells (Figure 
2.10A).  When SKBR3 FLAGKISS1R cells were treated with P-234, the dose response 
graph shifted to the left, indicating a decrease in cell viability similar to the response 
observed in SKBR3 pFLAG cells (Figure 2.10A).  Similarly, pretreatment of SKBR3 
FLAGKISS1R with MK-571 (an inhibitor of MRP1 and MRP4) or with a cocktail of 
inhibitors against all of the drug efflux transporters, decreased cell viability of SKBR3 
FLAGKISS1R cells to levels observed in SKBR3 pFLAG cells (Figure 2.10B-C).  
SKBR3 FLAGKISS1R cells had a significantly higher IC50 values when compared to 
pFLAG, and treatment of SKBR3 FLAGKISS1R cells with KISS1R antagonist or drug 
efflux transporter inhibitors restored cell sensitivity to doxorubicin (Figure 2.10D).   
The ability of KISS1R signaling to regulate drug resistance was tested in two 
other mammary cell lines.  The non-malignant MCF10A mammary epithelial cells have 
low endogenous KISS1R expression and therefore FLAGKISS1R was stably 
overexpressed in these cells, which promoted EMT and increased cell invasion, as 
previously described (1) (Figure 2.10A).  The TNBC, MDA-MB-231 metastatic breast 
cancer cells have high levels of endogenous expression (Figure 2.10A).  MCF10A 
FLAGKISS1R cells and MDA-MB-231 cells were pretreated overnight with P-234 and 
then treated with graded concentrations of doxorubicin.  We observed, that similar to 
SKBR3 FLAGKISS1R cells, MCF10A FLAGKISS1R cells had decreased sensitivity to 
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doxorubicin, compared to controls.  Additionally, we found that treatment of MCF10A 
FLAGKISS1R cells and MDA-MB-231 cells with P-234 increased drug sensitivity 
(Figure 2.11B).  MCF10A FLAGKISS1R cells had a significantly higher IC50 values 
when compared to MCF10A pFLAG cells, which was then decreased upon P-234 
treatment (Figure 2.11C).  Similarly, MDA-MB-231 cells had a significantly lower IC50 
value upon P-234 treatment (Figure 2.11C).  Overall, these results suggest that KISS1R 
expression and signaling contributes to drug resistance in ERα-negative mammary 
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Figure 2.10.  KISS1R signaling promoted drug resistance in SKBR3 breast cancer 
cells as determined using MTT cell viability assays.  A) SKBR3 pFLAG or 
FLAGKISS1R cells were pretreated with 1 µM P-234 (KISS1R antagonist) overnight or 
left untreated.  Cell viability was normalized to matching vehicle concentrations 
(DMSO).  B) Cells were pretreated for 10 minutes with 50 µM MK-571 (MRP1/4 
inhibitor) or left untreated.  Cells were then treated with varying concentrations of 
doxorubicin.  SKBR3 pFLAG cells were used as a control (n=5-7). C) FLAGKISS1R 
cells were pretreated for 10 minutes with drug efflux transporter inhibitory cocktail.  
Cells were then treated with varying concentrations of doxorubicin with and without drug 
efflux transporter inhibitors. Quantification of cell viability was normalized to matching 
vehicle concentrations (DMSO).  Two-way ANOVA followed by a Bonferonni post hoc 
test: a, P<0.05 for pFLAG vs FLAGKISS1R; b, P<0.05 FLAGKISS1R+P234 vs 
FLAGKISS1R; c, P<0.05 for FLAGKISS1R+MK-571 vs FLAGKISS1R; d, p<0.05 for 
FLAGKISS1R+Cocktail vs FLAGKISS1R.  D) Half of the maximal inhibitory 
concentration (IC50) was calculated for each individual curve.  One-way ANOVA 
followed by Dunnet’s multiple comparison test: *, P<0.05.  
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Figure 2.11.  KISS1R signaling induced drug resistance in non-malignant breast 
cells and TNBC cells.  A) Representative Western blots of protein expression of KISS1R 
in MCF10A pFLAG and FLAGKISS1R and MDA-MB-231 breast cancer cells.  B) 
MCF10A pFLAG or FLAGKISS1R and MDA-MB-231 cells were pretreated with 1 µM 
P-234 (KISS1R antagonist) overnight or left untreated.  Quantification of cell viability 
was normalized to matching vehicle concentrations (DMSO) (n=5-7). C) Half of the 
maximal inhibitory concentration (IC50) was calculated for each individual curve.  One-
way ANOVA followed by Dunnet’s multiple comparison test: *, P<0.05; Student’s 










KISS1R overexpression decreased sensitivity to erlotinib 
In 41-71% of TNBC patients, tumours overexpress EGFR, which is linked to the 
acquisition of a more invasive phenotype (24-27).  Small-molecular inhibitors that 
compete with ATP for intracellular domain binding to EGFR have been developed, such 
as erlotinib, which is a TKI that is currently used to treat non-small cell lung cancer, 
pancreatic cancer and is in clinical trials for breast cancer patients.  We investigated if 
KISS1R signaling promotes resistance to erlotinib in human breast cancer cells.  Indeed, 
we observed that SKBR3 FLAGKISS1R cells had increased resistance to erlotinib 
(Figure 2.12A).  When the IC50 values were evaluated, FLAGKISS1R cells had a 
significantly higher inhibitory concentration, compared to pFLAG control cells (Figure 
2.12B).  Our data thus indicates that KISS1R positively regulates EGFR levels and can 
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Figure 2.12.  Overexpression of KISS1R in SKBR3 cells decreased cell sensitivity to 
erlotinib. A) SKBR3 cells were treated with varying concentrations of erlotinib (n=8). 
Quantification of cell viability was normalized to matching vehicle concentrations 
(DMSO).  Two-way ANOVA followed by a Bonferonni post hoc test: *, P<0.05. B) Half 
of the maximal inhibitory concentration (IC50) was calculated for each individual curve.  















KISS1R overexpression increased prosurvival signaling 
Two signaling cascades commonly dysregulated in human carcinomas are the 
PI3K/Akt and Ras/ERK pathways (28, 29).  Up-regulation of pathways that promote cell 
proliferation, survival and apoptosis, can lead to drug resistance (30).  We first observed 
that SKBR3 FLAGKISS1R cells expressed significantly greater levels of anti-apoptotic 
protein, survivin, and increased the activity of prosurvival signaling molecules such as 
Akt and ERK, compared to controls (Figure 2.13).  This increase in prosurvival protein 
expression and activity could be one mechanism by which KISS1R signaling appears to 













Figure 2.13. KISS1R overexpression increased survivin and MAPK/ERK pathways 
in SKBR3 cells. Representative Western blots showing expression levels of survivin, 
ERK 1/2 and Akt (n=3-5).  Western blot analysis performed with rabbit anti-survivin, 
rabbit anti-pERK, rabbit anti-ERK, rabbit anti-pAkt and rabbit anti-Akt antibodies. 
Quantification of Western blot expression normalized to β-actin. Student’s unpaired T-













KISS1R signaling stimulated AXL expression and activity 
AXL is a member of the TAM receptor family of receptor tyrosine kinases and 
has been shown to stimulate breast cancer cell invasion, EMT, as well as drug resistance 
to doxorubicin and anti-EGFR therapies (31, 32).  Thus, we investigated whether 
KISS1R signaling regulates drug resistance via AXL.  We found that SKBR3 
FLAGKISS1R cells had increased AXL protein and mRNA expression, compared to 
pFLAG control cells (Figure 2.14A-B).  To evaluate a role for KISS1R signaling in 
regulating AXL mRNA expression, SKBR3 FLAGKISS1R were treated with P-234 and 
we observed that this led to decreased AXL mRNA (Figure 2.14B).  Similarly, treatment 
of TNBC MDA-MB-231 cells with P-234 significantly reduced AXL mRNA expression, 
compared to cells treated with the vehicle control (Figure 2.14C).     
Since GPCRs are known to activate receptor tyrosine kinases, we investigated if 
KISS1R signaling led to AXL activation.  Stimulation of MDA-MB-231 cells with 100 
nM of KP-10 appeared to increase AXL phosphorylation (Figure 2.15).  This 
phosphorylation was diminished, when cells were treated with the KISS1R antagonist P-
234  (Figure 2.15).  Overall, these findings indicate that KISS1R up-regulates AXL 
protein and mRNA expression, and may increase AXL activity in breast cancer cell lines.  
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Figure 2.14. KISS1R regulated AXL expression in human breast cancer cells. A) 
Representative Western blot showing overexpression of KISS1R in SKBR3 breast cancer 
cells results in increased AXL expression (n=6).  Western blot analysis performed using 
rabbit anti-AXL antibody.  Quantification of Western blot expression normalized to β-
actin.  Student’s unpaired T-test: *, P<0.05. Columns represent mean protein expression 
± SEM.  B) KISS1R activity regulates AXL mRNA in SKBR3 pFLAG and SKBR3 
FLAGKISS1R cells analyzed by RT-qPCR. SKBR3 pFLAG and SKBR3 FLAGKISS1R 
cells were serum-starved for 48 hours with the presence of 1 µM P-234 or vehicle control 
(n=3). Two-way ANOVA followed by Bonferroni post-hoc test: a, P<0.05 for pFLAG 
VEH vs FLAGKISS1R VEH; b, P<0.05 for FLAGKISS1R VEH vs FLAGKISS1R P-
234; c, P<0.05 for FLAGKISS1R P-234 vs pFLAG P-234. C) AXL mRNA in MDA-MB-
231 cells. Cells were serum-starved for 48 hours with the presence of 1 µM P-234 or 
vehicle control.  Total RNA was isolated and RT-qPCR was performed using primers for 
EGFR and GAPDH (n=3). Student’s unpaired T-test: *, P<0.05.  Columns represent 




Figure 2.15. KISS1R signaling activated AXL in MDA-MB-231 cells.  MDA-MB-231 
cells treated with 100 nM KP-10 for 0, 5 or 15 minutes, in the presence or absence of 1 
µM P-234.  AXL was imunoprecipitated and blots were probed with phosphorylated and 
total AXL. Quantification of phosphorylated AXL expression normalized to total AXL 



















KISS1R promoted drug resistance via AXL 
 To investigate a role for AXL in KISS1R-induced drug resistance, AXL protein 
was depleted using siRNA in SKBR3 FLAGKISS1R cells.  As AXL protein expression 
decreased, protein expression of KISS1R and EGFR remained unchanged (Figure 
2.16A).  Additionally, AXL knockdown in SKBR3 FLAGKISS1R cells restored 
chemosensitivity when compared to controls (Figure 2.16B).  When the IC50 values were 
evaluated for all cell lines and treatments, FLAGKISS1R siAXL cells had a significantly 
lower inhibitory concentration when compared to FLAGKISS1R control cells (Figure 
2.16C).  Overall, these findings suggest that KISS1R signals via AXL to induce 
chemoresistance.   Surprisingly, however, we did not see a change in drug efflux 
transporter expression in SKBR3 FLAGKISS1R cells upon depletion of AXL expression 
(Figure 2.17).  
Since AXL has been known to play critical roles in EMT, and EMT is linked to 
drug resistance of many types of cancer cells (33), we determined if AXL depletion in 
SKBR3 FLAGKISS1R cells regulated the expression of markers of EMT.  We found that 
AXL knockdown resulted in a significant decrease in Snail-Slug protein expression, but 
not vimentin, compared to control cells (Figure 2.17).  Overall, these results suggest that 
AXL activity and expression is up-regulated by KISS1R expression and signaling, and 
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Figure 2.16. Depletion of AXL in FLAGKISS1R cells restored chemosensitivity. A) 
Representative Western blots showing protein expression of AXL, KISS1R, EGFR and 
efflux transporters in FLAGKISS1R cells transfected with AXL siRNA (n=3-6).  
Student’s unpaired T-test: *, P<0.05. B) FLAGKISS1R cells transfected with AXL 
siRNA or scrambled control were treated with graded concentrations of doxorubicin 
(n=3). Quantification of cell viability was normalized to matching vehicle concentrations 
(DMSO).  Two-way ANOVA followed by a Bonferonni post hoc test: a, P<0.05 for 
pFLAG vs FLAGKISS1R Scrambled; b, P<0.05 for FLAGKISS1R siAXL vs 
FLAGKISS1R Scrambled; C) Half of the maximal inhibitory concentration (IC50) was 
calculated for each individual curve.  One-way ANOVA followed by Dunnet’s multiple 










Figure 2.17. Depletion of AXL in FLAGKISS1R cells did not affect efflux 
transporter expression but partially reversed EMT. Representative Western blots 
showing endogenous protein expression of AXL, BCRP, MRP4, MRP1, vimentin and 
Snail-Slug in FLAGKISS1R cells transfected with AXL siRNA, compared to 
FLAGKISS1R cells transfected with control siRNA (n=3).  Quantification of Western 
blot expression normalized to β-actin. Student’s unpaired T-test: *, P<0.05. Columns 
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3.1 Summary of Novel Findings and Conclusions 
 Although recent studies indicate that KISS1R signaling correlates positively with 
breast tumour progression and metastatic potential (1-4), it is unknown whether KISS1R 
stimulates breast cancer cell drug resistance.  Our data suggest that KISS1R signaling 
increases EGFR expression and promotes drug resistance of ERα-negative breast cancer 
cells.  We show for the first time that KISS1R increases breast cancer cell resistance to 
the conventional chemotherapy, doxorubicin, as well as the anti-EGFR therapy, erlotinib.   
This increased resistance may be due to a KISS1R-dependent up-regulation of drug 
efflux transporter expression and function as well as increased expression and activation 
of AXL.  Since KISS1R signaling is now implicated in the promotion of metastasis and 
drug resistance, two major factors leading to poor breast cancer patient prognosis, it may 
be an extremely important drug target, which could improve treatment of TNBC patients.   
Objective #1: To investigate if KISS1R signaling positively regulates EGFR expression 
and to begin to elucidate the molecular mechanism 
 We demonstrated that KISS1R overexpression in SKBR3 breast cancer cells 
resulted in increased EGFR mRNA and protein expression. Furthermore, our results 
suggest that KISS1R activity regulated this process since EGFR mRNA levels were 
reduced in the presence of the KISS1R antagonist.  Interestingly, we found that KISS1R 
overexpression increased nuclear localization of transcription factors SP-1 and NF-κB, 
both of which have been shown to up-regulate EGFR transcription (5).  KISS1R 
overexpression also resulted in increased binding of SP-1 and RNA Pol II to the EGFR 
promoter, as demonstrated by ChIP.  Overall these results indicate that KISS1R promotes 
EGFR transcription in ERα-negative breast cancer cells. 
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Objective #2: To determine if KISS1R signaling promotes breast cancer drug resistance 
 We demonstrated that KISS1R signaling resulted in decreased doxorubicin 
accumulation in SKBR3 cells, and lowered the sensitivity of cells to this conventional 
chemotherapeutic, through up-regulating drug efflux transporter expression and function.  
KISS1R overexpression also increased drug resistance to erlotinib, an anti-EGFR 
therapeutic.  These results show for the first time that KISS1R signaling promotes drug 
resistance. Additionally, KISS1R signaling increased the expression of anti-apoptotic 
proteins including Akt and survivin.  We identified AXL as new signaling partner in the 
KISS1R pathway, and demonstrated that KISS1R signaling positively regulates AXL 
expression and activity. AXL depletion in KISS1R overexpressing cells restored 
chemosensitivity, possibly by the partial reversal of EMT.  Thus, our results reveal 
potential mechanisms by which KISS1R signaling promotes breast cancer drug 
resistance, by regulating the expression of drug efflux transporters and also by activating 
AXL. 
 
3.2 Contributions of Research to Current State of Knowledge 
 Cell surface receptors are an integral part of signaling systems, allowing 
extracellular signals to be turned into intracellular responses.  Two major classes of these 
cell surface receptors include GPCRs and RTKs (6).  Interestingly, cross-communication 
between these two receptor groups can occur, synergistically or antagonistically, 
facilitating many complex signaling responses and resulting in a wide range of 
physiological and pathological cellular events (6, 7).  The activation of GPCRs has been 
shown to stimulate RTK activity by a molecular mechanism termed ‘transactivation’.  
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GPCR signaling was first demonstrated to increase RTK activity when Rat-1 fibroblasts 
were stimulated with GPCR agonists, endothelin-1, lysophasphatic acid and thrombin, 
and EGFR tyrosine phosphorylation rapidly increased (8).  It is now understood that 
GPCRs can transactivate RTKs through a variety of mechanisms, including increasing 
intracellular reactive oxygen species, MMP-dependent release of RTK ligands, increased 
Ca2+ mobilization, or by non-RTKs, including Src (6, 9).   
EGFR is an RTK that is overexpressed in numerous cancers.  EGFR signaling 
results in increased cell proliferation, invasion and metastasis and angiogenesis (9, 10).  
Specifically in TNBC, EGFR overexpression is seen in 41-71% of patients (11-14). This 
makes EGFR a highly favourable drug-target due to its role in many oncogenic pathways, 
specifically in TNBC patients, where targeted therapy is limited.  Unfortunately, 
however, inhibition of EGFR alone, targeting either the extracellular domain or the 
tyrosine kinase domain, has resulted in poor clinical outcomes due to acquired resistance 
to these agents (15).  Our lab has previously established a role of KISS1R in regulating 
breast cancer cell invasion via EGFR transactivation in TNBC cells (2, 3).  Our previous 
work demonstrated that KP-10 transactivates EGFR, via scaffolding proteins β-arrestin 2 
and IQGAP, leading to breast cancer cell invasion (2, 3).  Since KISS1R appears to be 
increasing breast cancer cell invasion in an EGFR-dependent mechanism, perhaps 
targeting both receptors simultaneously could lead to increased efficacy compared to 





Role of KISS1R Signaling in Regulating EGFR Expression in Breast Cancer 
EGFR protein is overexpressed in TNBC patients resulting in increased EGFR 
signaling and therefore tumourigenesis in TNBC patients (11-14).  EGFR overexpression 
in TNBC patients is rarely caused by increased gene copy number or activating mutations 
(16, 17).  The overexpression of EGFR is therefore possibly due to regulation at the 
transcriptional and translational level.  Similarly, in breast cancer cell lines, it has been 
shown that EGFR mRNA levels correlate with the amount of receptor protein expressed, 
and that these differences are controlled at the transcriptional level (18).  Due to the short 
half-life of EGFR mRNA (approximately 1-2 hours), post-transcriptional regulation, 
possibly through modification of mRNA stability, is thought to play only a small role in 
EGFR protein expression (19, 20).  Therefore, variations in transcription rates are thought 
to be the major determining factor regulating EGFR protein expression.  We have 
demonstrated that KISS1R signaling up-regulates EGFR mRNA and protein levels and 
this was regulated by KISS1R activity, since this effect was inhibited in the presence of 
the KISS1R antagonist.   Surprisingly, EGFR mRNA expression in SKBR3 
FLAGKISS1R cells was not further increased with KP-10 stimulation (Supplementary 
Figure 1).  The lack of further increase in EGFR mRNA with KP-10 treatment could be 
due to the high basal kisspeptin expression seen in SKBR3 FLAGKISS1R cells.  Thus 
these findings indicate that KISS1R signaling regulates EGFR expression by increasing 
EGFR gene transcription. 
The EGFR gene has been well characterized, spanning 110 kilobases and 
consisting of 26 exons (21).  The promoter region lacks the traditional TATA or CAAT 
boxes, the most common promoter elements, and therefore transcription initiation begins 
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at 6-7 sites in the 50-250 base pairs region upstream of the ATG translation start codon 
(22).  Interestingly, the most common transcription initiation site in vivo is more distal, 
compared to the most common in vitro transcriptional initiation site, located 
approximately 50 base pairs upstream of the start codon (19).  A number of transcription 
factors have been shown to bind to the EGFR promoter region, including TCF, ETF1-2, 
GCF, ETR, AP-2 and SP-1 and NF-κB (19).  Additionally, EGFR gene transcription is 
also regulated by a number of hormones and growth factors, including progesterone and 
vitamin D (19, 23).   
Although the EGFR promoter region has been characterized since the 1980s and 
some mechanisms have been proposed for increased EGFR transcription, the molecular 
mechanisms by which EGFR transcription is increased in TNBC patients is largely 
unknown.  Our results demonstrate that KISS1R signaling promotes EGFR transcription 
and expression possibly by regulating transcription factors SP-1 and NF-κB.  
Specifically, four SP-1 binding sites were found upstream of the EGFR start site and it 
was demonstrated that SP-1 binding to the EGFR promoter region was required for 
maximal expression (5).  Additionally, SP-1 and EGFR expression in human breast 
tumours was correlated with increased tumour grade and poor prognosis (24).  Similar 
findings were shown in human gastric carcinoma cell lines and gastric carcinoma tissues 
as well (25).   Furthermore, we have demonstrated that recruitment of SP-1 and RNA Pol 
II to the EGFR promoter was increased with KISS1R overexpression in breast cancer 
cells.  To the best of our knowledge, this is the first study to demonstrate KISS1R 
enhances SP-1 and RNA Pol II binding in order to increase EGFR expression.  Although 
we have only investigated SP-1 and RNA Pol II binding at the SP-1 binding site most 
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proximal to the start codon (our primer encompassed -129 to -23 base pairs), the most 
common transcription initiation start site in vitro is also located within that region (22).  
Additionally, RNA Pol II enrichment on the EGFR promoter has also been shown to 
occur within -240 to -70 base pairs upstream of the start codon in LNCaP prostate cancer 
cells, which correlated with increased EGFR expression (26).  Lastly, characterization of 
the EGFR promoter by deletion analysis revealed that only the region between -178 and -
16 base pairs was required to have sufficient promoter activity and EGFR expression 
(27).  Overall, our studies uncover a role for KISS1R in not only activating EGFR, but 
also up-regulating EGFR expression, via increased SP-1 nuclear recruitment of SP-1.  
KISS1R may be an excellent receptor to target in order to decrease EGFR-driven 
tumourigenesis, particularly in TNBC patients. 
 
KISS1R Signaling in Promoting Breast Cancer Drug Resistance 
The development of drug resistance in human carcinomas is the most difficult 
obstacle to overcome, specifically in patients whose primary tumour or distant metastases 
have not been fully surgically removed.  Uncovering the molecular mechanisms that 
drive tumour drug resistance is essential in order to be able to develop targeted therapies 
that can disrupt resistance and restore drug sensitivity.  Although EGFR has been shown 
to increase cancer cell migration and metastases, it has been shown to also promote cell 
survival and drug resistance (10).  The role of EGFR in regulating tumour drug 
sensitivity has been debated in the past, however, the majority of studies demonstrate 
restored drug sensitivity upon EGFR inhibition (10).  Blocking EGFR through antibodies 
increased sensitivity of human tumour xenografts to cisplatin using human breast cancer 
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cells, MDA-MB-468, and human mouth epidermal cancer cells, KD (28, 29).  Baselga 
and colleagues used mice with subcutaneous xenografts of A431 epidermoid carcinoma 
cells to demonstrate that EGFR blockade resulted in increased sensitivity to doxorubicin.  
Tumours treated with combinational therapy of doxorubicin plus an anti-EGFR inhibitory 
antibody, resulted in complete eradication of tumours in all animals, whereas 
monotherapies of either treatment results in only a modest reduction of tumour growth 
(30).   
Since our results demonstrated that KISS1R positively regulates EGFR 
expression in ERα-negative human breast cancer cells, we sought to investigate if 
KISS1R signaling played a role in regulating drug resistance.  We found that KISS1R 
signaling in SKBR3 cells promoted the intracellular accumulation of doxorubicin and 
doxorubicin resistance.  Using multiple cell lines (SKBR3 FLAGKISS1R, MCF10A 
FLAGKISS1R and MDA-MB-231 cells) we demonstrated that KISS1R activity regulated 
drug resistance, since doxorubicin sensitivity was restored in the presence of KISS1R 
antagonist. We found that KISS1R signaling resulted in an up-regulation of drug efflux 
transporters BCRP, MRP1 and MRP4 and the activity of these transporters was necessary 
for mediating drug resistance.  Currently, we do not know whether increased EGFR 
expression leads to elevated levels of drug efflux transporters in ERα-negative cells.  
However, other studies have reported that EGFR overexpression can regulate drug efflux 
transporter-dependent multi drug resistance in cancer cells (31).  When drug resistant 
BCRP overexpressing MCF-7 cells were treated with apatanib, a TKI, BCRP transport 
function of doxorubicin was decreased (31).  Thus, KISS1R signaling leads to an increase 
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in EGFR expression and this may up-regulate drug efflux transporters, which will 
contribute to the multidrug resistance phenotype (Figure 3.1).   
Currently, a single study has investigated a potential role for kisspeptin signaling 
in cancer drug resistance.  Jiffar and colleagues developed a cisplatin resistant head and 
neck squamous cell carcinoma (HNSCC) cell line by exposing HNSCC cell lines to 
escalating doses of cisplatin for 6 months (32).  These cisplatin resistant HNSCC, as well 
as the parental line, were utilized in a orthotopic mouse model.  Cisplatin resistant cells 
displayed increased primary tumour growth and increased metastasis that lead to 
decreased overall survival (32).  Next, through real-time PCR and Western blot analysis, 
KISS1 mRNA expression was shown to be decreased in cisplatin resistant HNSCC cells 
compared to the control.  Similarly, through small interfering RNA (siRNA) depletion of 
KISS1 in the parental HNSCC cell line, cells became partially resistant to cisplatin (32).  
Overall, this study suggests a role for KISS1 expression in regulating cisplatin drug 
resistance as well as metastasis in HNSCC.  Although this study is in contrast to our 
current findings, kisspeptin/KISS1R signaling in ERα-negative breast cancer has shown 
to be detrimental, promoting cell invasion, breast tumour grade, as well as poor patient 
prognosis,  whereas the KISS1R system is anti-metastatic in other cancers.  Therefore it 
should not be surprising that the role of kisspeptin/KISS1R signaling in breast cancer 
drug resistance differs from the role this signaling system plays in other tumour types. 
 
KISS1R Signaling Promotes Cell Survival  
Two of the most dysregulated signaling cascades in human carcinomas are the 
PI3K/Akt and Ras/ERK pathways (33, 34).  These pathways are cascades of kinases that 
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become active through phosphorylation and are therefore regulated by other kinases, 
phosphatases as well as scaffolding proteins (35).  These pathways play key roles in 
promoting cell proliferation, survival and apoptosis, and therefore overactivation of these 
pathways can lead to drug resistance (36).  Not only are both of these pathways 
downstream of growth factor receptors, including EGFR, which are commonly 
overexpressed in cancers, but also many downstream components can be altered, leading 
to increased tumourigenesis and resistance to therapies (35).  Here, we have reported that 
KISS1R overexpression in SKBR3 cells could increase cell survival by increasing 
PI3K/Akt and Ras/ERK pathway signaling as seen by an increase in phosphorylated Akt 
and ERK proteins.  Although in our system, we can’t rule out that the increase in 
phosphorylated Akt and ERK could be due to the overexpression and increased activity 
of EGFR, both Akt and ERK have been shown to signal downstream of KISS1R as well 
(1).      
In addition to increasing these cell survival signaling cascades, we found that 
KISS1R overexpression increased the expression of the anti-apoptotic protein, survivin.    
Survivin, a member of the Inhibitors of Apoptosis Proteins family, controls cell 
proliferation, inhibition of apoptosis as well as promotion of angiogenesis (37).  The 
overexpression of survivin has been demonstrated in numerous tumours, including breast 
(37).  Patients shown to have increased survivin expression are associated with shorter 
survival, increased risk of recurrence and resistance to therapies (37).  Interestingly, the 
PI3K/Akt pathway has been shown to up-regulate survivin expression in breast cancer, as 
sustained Akt activation resulted in a dramatic increase in surivivin expression (38).  
Additionally, survivin expression is positively correlated with EGFR expression in breast 
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tumours (38).  Lastly, the PI3K/Akt pathway has also been implicated in facilitating drug 
resistance through the up-regulating drug efflux transporter, P-gp in breast cancer cells 
(39).  Treatment of MCF-7 doxorubicin resistant breast cancer cells, with a PI3K 
inhibitor, decreased survivin as well as P-gp expression and restored cell sensitivity to 
doxorubicin (39).  Although we did not see an increase in P-gp expression upon KISS1R 
overexpression (Supplementary Figure 2), perhaps the PI3K/Akt pathway could be 
regulating other drug efflux transporters as well.  Our findings indicate that KISS1R 
could be signaling through EGFR to increase survivin as well as drug efflux transporter 
expression and therefore promote drug resistance through multiple mechanisms.     
 
KISS1R Signaling Up-regulates AXL leading to Drug Resistance  
 AXL is another RTK that has been implicated in regulating tumourigenesis in 
many cancers, due to its role in promoting cell proliferation and survival.  Overexpression 
of AXL has been reported in numerous cancers, including breast, and has been shown to 
correlate with poor patient prognosis, as well as increased invasiveness and xenograft 
growth of human cancers (40).  Interestingly, both of the oncogenic signaling pathways, 
PI3K/Akt and Ras/ERK, also signal downstream of AXL (40).  Our results indicate that 
KISS1R signaling can positively regulate AXL expression of human breast cancer cells, 
as demonstrated in SKBR3 and MDA-MB-231 cells.  By up-regulating AXL expression, 
which can lead to increased signaling via the P13K/Akt and Ras/ERK pathways, KISS1R 
signaling can promote drug resistance of breast cancer cells.  It is also therefore not 
surprising that AXL overexpression has also been shown to promote drug resistance of 
breast cancer (41).  These studies support our findings that in SKBR3 FLAGKISS1R 
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cells, AXL depletion restores sensitivity to doxorubicin.  Surprisingly, however, is that in 
AXL depleted SKBR3 FLAGKISS1R cells, there was no change in drug efflux 
transporter expression.  This could possibly be due to the very long half-life of the drug 
efflux transporters (42), and therefore the 48-hour time point of AXL siRNA transfection 
was not long enough to see an effect the protein level of these transporters.  
 Alternatively, since there was no change in drug efflux transporter expression 
upon AXL depletion, we explored other mechanisms by which AXL could be regulating 
drug resistance.  AXL can positively regulate EMT in many cancers (43-45). We have 
demonstrated previously, that KISS1R signaling also promotes an EMT-like phenotype 
(2).  In order to elucidate if KISS1R is regulating EMT via AXL, expression of markers 
of EMT, including vimentin and Snail-Slug were investigated in AXL depleted SKBR3 
FLAGKISS1R cells.  Although vimentin protein expression was not changed, Snail-Slug 
was significantly decreased upon AXL depletion.  Thus we propose that AXL may 
promote drug resistance by regulating EMT.  This is supported by Li and colleagues, who 
demonstrated that depletion of AXL in MDA-MB-231 cells decreased PI3K/Akt 
signaling, resulting in a decrease of Slug expression, which suppressed breast cancer cell 
invasion and restored drug sensitivity (46).  Additionally, although AXL signaling has 
been shown to increase vimentin protein expression in DU145, human prostate cancer 
cells, AXL-induced vimentin expression was through a Snail-Slug-dependent 
mechanism, as vimentin was not overexpressed when Snail-Slug was depleted (47).  Our 
short length of AXL depletion, 48 hours, may have only been enough time to decrease 
Snail-Slug expression, whereas extended AXL silencing may result in decreased 
expression of proteins downstream of Snail-Slug, including vimentin.       
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EMT has been shown to drive drug resistance in a number of human breast cancer 
cells (48).  EMT-mediated drug resistance is through a variety of mechanisms, some 
being the positive regulation of drug efflux transporter expression and activity, and 
another being through increasing breast cancer cell stem-like properties (48).  Fang and 
colleagues reported that by transfecting MCF-7 and MCF-10A breast cancer cells with 
Twist, a transcription factor that promotes EMT, cells had increased stem-like profiles, 
indicated by a high expression of CD44 and low expression of CD24 (CD44+/CD24-) 
(49).  Additionally, breast cancer cells exogenously expressing Twist also had an up-
regulation of MRP1, again, implicating EMT in drug resistance (49).  Similarly, 
exogenous expression of Snail, in non-tumourigenic human mammary epithelial cells, 
HMLE, resulted cells with self-renewing capacities and a CD44+/CD24- profile (50).  
These studies and our findings indicate that the ability of KISS1R to up-regulate AXL 
could be promoting drug resistance in an EMT-mediated pathway.  Whether KISS1R 
signaling promotes stemness is currently unknown and studies investigating this are 
underway. 
 
3.3 Limitations and Future Directions 
Our research has revealed a possible role for KISS1R signaling in breast cancer 
drug resistance.  Although we have proposed many potential mechanisms, most of which 
are regulated by EGFR and AXL, further research must be performed to fully understand 
how kisspeptin/KISS1R signaling is regulating drug resistance.  Specifically, a loss-of-
function approach can be taken to determine whether depletion of KISS1R in TNBC cells 
(MDA-MB-231 and Hs578t) can restore drug sensitivity.  Additionally, the use of 
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alternative experiments that also assess cell sensitivity to therapies, such as the 
clonogenic cell survival assay, could be performed in order to further validate the role of 
KISS1R in promoting drug resistance (51).  Muir and colleagues initially demonstrated 
that nitric oxide mimetics could sensitize MDA-MB-231 breast cancer cells, cultured in a 
monolayer as well as spheroids, to doxorubicin through clonogenic assay (52).  
Performing spheroid clonogenic assays better mimics the heterozygosity of tumour cells 
in vivo, due to the different rates of proliferation of the cells on the outer and inner layer 
of the spheroids (53).    
Further knowledge regarding EGFR regulation could also be obtained by 
determining the SP-1 nuclear recruitment on other SP-1 sites, or examining the role of 
additional transcription factors, such as NF-κB, on the EGFR promoter by ChIP 
experiments.   Additionally, the effect of KISS1R signaling on SP-1 nuclear recruitment 
could be examined by pre-treating SKBR3 FLAGKISS1R cells with KISS1R antagonist, 
P234, or by depleting KISS1R in TNBC cells. 
Lastly, to investigate if KISS1R promotes drug resistance in vivo, studies must be 
performed in an animal model.   Subcutaneous xenografts could be established in nude 
mice, by injecting SKBR3 FLAGKISS1R and control cells.  Once tumours reached a 
certain size, animals would be treated with doxorubicin and primary tumour size would 
be measured to determine the sensitivity of SKBR3 cells to doxorubicin.  Tumour tissue 
could be collected and immunohistochemistry could be performed to see if kisspeptin or 
KISS1R expression correlated with drug resistance.  Similar xenograft studies were 
performed with BT-474 breast cancer cells in order to determine if trastuzumab resistance 
correlated with HER-2 overexpression (54).   
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3.4 Conclusions 
Our results demonstrate for the first time that KISS1R signaling regulates human 
breast cancer drug resistance to conventional therapeutics such as doxorubicin as well as 
the anti-EGFR therapy, erlotinib.  This KISS1R-induced drug resistance could be 
mediated through regulating EGFR and/or AXL expression, leading to increased drug 
efflux transporter expression and increased cell survival signaling (Figure 3.1).  Thus, 










































Figure 3.1. Our proposed model for KISS1R signaling promoting drug resistance in 
TNBC.  KISS1R signaling increases the expression of drug efflux transports as well as 
the expression and activity of RTKs, EGFR and AXL. AXL has been shown to increase 
drug resistance. Additionally, KISS1R signaling regulates a variety of cell survival 
pathways leading to increased P13K/Akt and Ras/ERK signaling, as well as increased 
survivin expression.  KISS1R signaling also increases EMT and the expression of drug 
efflux transporters. Taken together, activation of these pathways can promote drug 
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Supplementary Figure 1.  Kisspeptin-10 stimulation does not alter EGFR mRNA 
expression in SKBR3 cells. EGFR mRNA in SKBR3 pFLAG and FLAGKISS1R cells 
analyzed by RT-qPCR. SKBR3 pFLAG and FLAGKISS1R cells were grown in the 
presence of 100 nM KP-10 for 24, 48 or 72 hours in complete media (n=3). Columns 





Supplementary Figure 2. KISS1R overexpression did not increase P-gp protein 
expression in SKBR3 cells.  Relative protein expression of P-gp as identified by 
Western blot analysis (n=3). Columns represent mean relative protein expression, 






Supplementary Figure 3. P-234 treatment did not alter MRP1 mRNA expression in 
SKBR3 FLAGKISS1R cells. MRP1 mRNA expression in SKBR3 pFLAG and SKBR3 
FLAGKISS1R cells treated in serum free media for 48 hours in the presence of 1uM P-
234 or 20% acetonitrile (VEH) control. Total RNA was isolated from SKBR3 cells and 
RT-qPCR was performed using primers for MRP1 and GAPDH (n=5).  Columns 
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